US3975537A - Pharmaceutical compositions and methods of producing coronary vasodilation - Google Patents
Pharmaceutical compositions and methods of producing coronary vasodilation Download PDFInfo
- Publication number
- US3975537A US3975537A US05/551,581 US55158175A US3975537A US 3975537 A US3975537 A US 3975537A US 55158175 A US55158175 A US 55158175A US 3975537 A US3975537 A US 3975537A
- Authority
- US
- United States
- Prior art keywords
- benzofuran
- lower alkyl
- hydrogen
- butyl
- propoxybenzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 230000024883 vasodilation Effects 0.000 title claims abstract description 8
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims abstract description 247
- 150000001907 coumarones Chemical class 0.000 claims abstract description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 239000001257 hydrogen Substances 0.000 claims description 49
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000001589 carboacyl group Chemical group 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical group 0.000 claims description 11
- -1 piperidino, pyrrolidino, morpholino Chemical group 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 239000003218 coronary vasodilator agent Substances 0.000 claims description 6
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 101000701936 Homo sapiens Signal peptidase complex subunit 1 Proteins 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 11
- 230000003257 anti-anginal effect Effects 0.000 claims 2
- 102100030313 Signal peptidase complex subunit 1 Human genes 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 59
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000004593 Epoxy Substances 0.000 description 48
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 45
- 239000000203 mixture Substances 0.000 description 41
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 38
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 230000000875 corresponding effect Effects 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 230000017858 demethylation Effects 0.000 description 20
- 238000010520 demethylation reaction Methods 0.000 description 20
- 150000002924 oxiranes Chemical class 0.000 description 19
- 239000000284 extract Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 238000007142 ring opening reaction Methods 0.000 description 17
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 15
- 230000010933 acylation Effects 0.000 description 13
- 238000005917 acylation reaction Methods 0.000 description 13
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 13
- 238000001816 cooling Methods 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- LTHMASCHPKLOPL-UHFFFAOYSA-N 1-benzofuran-2-yl-(2-hydroxyphenyl)methanone Chemical compound OC1=CC=CC=C1C(=O)C1=CC2=CC=CC=C2O1 LTHMASCHPKLOPL-UHFFFAOYSA-N 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- OVJKFJDEVKABNF-UHFFFAOYSA-N 2-butyl-1-benzofuran Chemical compound C1=CC=C2OC(CCCC)=CC2=C1 OVJKFJDEVKABNF-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- ZHGKQUXXASLVQQ-UHFFFAOYSA-N (2-Butylbenzofuran-3-yl)(4-hydroxyphenyl)ketone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 ZHGKQUXXASLVQQ-UHFFFAOYSA-N 0.000 description 7
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- JJXPTUWJVQUHKN-UHFFFAOYSA-N 5-methoxy-1-benzofuran Chemical compound COC1=CC=C2OC=CC2=C1 JJXPTUWJVQUHKN-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- FLAYZKKEOIAALB-UHFFFAOYSA-N 2-bromo-1-(4-chlorophenyl)ethanone Chemical compound ClC1=CC=C(C(=O)CBr)C=C1 FLAYZKKEOIAALB-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 4
- AKRGXGBDYAXGGW-UHFFFAOYSA-N [2-[(4-aminophenyl)methyl]-1-benzofuran-3-yl]-(4-hydroxyphenyl)methanone Chemical compound C1=CC(N)=CC=C1CC1=C(C(=O)C=2C=CC(O)=CC=2)C2=CC=CC=C2O1 AKRGXGBDYAXGGW-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- OHXAOPZTJOUYKM-UHFFFAOYSA-N 3-Chloro-2-methylpropene Chemical compound CC(=C)CCl OHXAOPZTJOUYKM-UHFFFAOYSA-N 0.000 description 3
- GAPGQBDURBPRLG-UHFFFAOYSA-N 3-chloro-4-methoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1Cl GAPGQBDURBPRLG-UHFFFAOYSA-N 0.000 description 3
- CPJOPFBXUHIQQL-UHFFFAOYSA-N 5-chloro-1-benzofuran Chemical compound ClC1=CC=C2OC=CC2=C1 CPJOPFBXUHIQQL-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- LATNSMOHUOVBCB-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(2-hydroxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=CC=C1O LATNSMOHUOVBCB-UHFFFAOYSA-N 0.000 description 2
- YKSHEZAHMWWCGP-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(3,5-dibromo-4-hydroxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 YKSHEZAHMWWCGP-UHFFFAOYSA-N 0.000 description 2
- VOMMPAOXOAPCPK-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(3,5-dichloro-4-hydroxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Cl)=C(O)C(Cl)=C1 VOMMPAOXOAPCPK-UHFFFAOYSA-N 0.000 description 2
- RCDJYBQVTKKQTD-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(3-methoxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=CC(OC)=C1 RCDJYBQVTKKQTD-UHFFFAOYSA-N 0.000 description 2
- JRENHDKJTPIAMB-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(4-chloro-2-hydroxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1O JRENHDKJTPIAMB-UHFFFAOYSA-N 0.000 description 2
- WCICYXQEZMVXRM-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(4-hydroxy-3-methoxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C(OC)=C1 WCICYXQEZMVXRM-UHFFFAOYSA-N 0.000 description 2
- TUSUGUWBJFZFSG-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(4-hydroxy-3-methylphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C(C)=C1 TUSUGUWBJFZFSG-UHFFFAOYSA-N 0.000 description 2
- GGILSPPLGHSONP-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(4-methoxy-3,5-dimethylphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(C)=C(OC)C(C)=C1 GGILSPPLGHSONP-UHFFFAOYSA-N 0.000 description 2
- CTWMHJFSJRHLLR-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(4-methoxy-3-methylphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(OC)C(C)=C1 CTWMHJFSJRHLLR-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- YVNYNJCKYRTYFU-UHFFFAOYSA-N (3-bromo-4-hydroxyphenyl)-(2-butyl-1-benzofuran-3-yl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C(Br)=C1 YVNYNJCKYRTYFU-UHFFFAOYSA-N 0.000 description 2
- DIYZTNNJFLODOI-UHFFFAOYSA-N (4-hydroxyphenyl)-[2-(3-nitrophenyl)-1-benzofuran-3-yl]methanone Chemical compound C1=CC(O)=CC=C1C(=O)C1=C(C=2C=C(C=CC=2)[N+]([O-])=O)OC2=CC=CC=C12 DIYZTNNJFLODOI-UHFFFAOYSA-N 0.000 description 2
- YLAJBTJTTNARBR-UHFFFAOYSA-N (4-hydroxyphenyl)-[2-[(4-nitrophenyl)methyl]-1-benzofuran-3-yl]methanone Chemical compound C1=CC(O)=CC=C1C(=O)C(C1=CC=CC=C1O1)=C1CC1=CC=C([N+]([O-])=O)C=C1 YLAJBTJTTNARBR-UHFFFAOYSA-N 0.000 description 2
- ABEDUINFUWIUNI-UHFFFAOYSA-N (4-methoxyphenyl)-(3-methyl-1-benzofuran-2-yl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(C)C2=CC=CC=C2O1 ABEDUINFUWIUNI-UHFFFAOYSA-N 0.000 description 2
- VNWLMVAHYLPUQH-UHFFFAOYSA-N (4-methoxyphenyl)-(3-phenyl-1-benzofuran-2-yl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(C=2C=CC=CC=2)C2=CC=CC=C2O1 VNWLMVAHYLPUQH-UHFFFAOYSA-N 0.000 description 2
- YFEZJYVQHHINPR-UHFFFAOYSA-N 1-(5-chloro-1-benzofuran-2-yl)butan-1-one Chemical compound ClC1=CC=C2OC(C(=O)CCC)=CC2=C1 YFEZJYVQHHINPR-UHFFFAOYSA-N 0.000 description 2
- REYIPJAVPHZYCV-UHFFFAOYSA-N 1-benzofuran-2-yl-(3-chloro-4-hydroxyphenyl)methanone Chemical compound C1=C(Cl)C(O)=CC=C1C(=O)C1=CC2=CC=CC=C2O1 REYIPJAVPHZYCV-UHFFFAOYSA-N 0.000 description 2
- FQHJAAOLWZILJU-UHFFFAOYSA-N 1-benzofuran-2-yl-(4-chlorophenyl)methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC2=CC=CC=C2O1 FQHJAAOLWZILJU-UHFFFAOYSA-N 0.000 description 2
- XJQLOIGEZXCUND-UHFFFAOYSA-N 1-benzofuran-2-yl-(4-nitrophenyl)methanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)C1=CC2=CC=CC=C2O1 XJQLOIGEZXCUND-UHFFFAOYSA-N 0.000 description 2
- VLLADTXGBAUFMW-UHFFFAOYSA-N 1-benzofuran-3-carbonitrile Chemical compound C1=CC=C2C(C#N)=COC2=C1 VLLADTXGBAUFMW-UHFFFAOYSA-N 0.000 description 2
- VJJAGAVQYBKEPY-UHFFFAOYSA-N 1-ethynyl-3-nitrobenzene Chemical compound [O-][N+](=O)c1cccc(c1)C#[C-] VJJAGAVQYBKEPY-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OZLBYTULGSQLCJ-UHFFFAOYSA-N 2-(3-nitrophenyl)-1-benzofuran Chemical compound [O-][N+](=O)C1=CC=CC(C=2OC3=CC=CC=C3C=2)=C1 OZLBYTULGSQLCJ-UHFFFAOYSA-N 0.000 description 2
- XQIZMTAULIROTK-UHFFFAOYSA-N 2-[(4-nitrophenyl)methyl]-1-benzofuran Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC1=CC2=CC=CC=C2O1 XQIZMTAULIROTK-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- HFGUMVYWWPOKKI-UHFFFAOYSA-N 2-[[3-(trifluoromethyl)phenyl]methyl]-1-benzofuran Chemical compound FC(F)(F)C1=CC=CC(CC=2OC3=CC=CC=C3C=2)=C1 HFGUMVYWWPOKKI-UHFFFAOYSA-N 0.000 description 2
- JECYUBVRTQDVAT-UHFFFAOYSA-N 2-acetylphenol Chemical compound CC(=O)C1=CC=CC=C1O JECYUBVRTQDVAT-UHFFFAOYSA-N 0.000 description 2
- TZIYNLSEBAYCBZ-UHFFFAOYSA-N 2-bromo-1-[3-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=CC(C(=O)CBr)=C1 TZIYNLSEBAYCBZ-UHFFFAOYSA-N 0.000 description 2
- KMAGJAHANFYLHE-UHFFFAOYSA-N 2-butyl-5-chloro-1-benzofuran Chemical compound ClC1=CC=C2OC(CCCC)=CC2=C1 KMAGJAHANFYLHE-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- HXMZLDUBSSPQIB-UHFFFAOYSA-N 2-phenyl-1-benzofuran Chemical compound O1C2=CC=CC=C2C=C1C1=CC=CC=C1 HXMZLDUBSSPQIB-UHFFFAOYSA-N 0.000 description 2
- QGNLHMKIGMZKJX-UHFFFAOYSA-N 3-chloro-4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(Cl)=C1 QGNLHMKIGMZKJX-UHFFFAOYSA-N 0.000 description 2
- IBCQUQXCTOPJOD-UHFFFAOYSA-N 3-chloro-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1Cl IBCQUQXCTOPJOD-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- NWCMFNIMUUMBGZ-UHFFFAOYSA-N 4-methoxy-1-benzofuran Chemical compound COC1=CC=CC2=C1C=CO2 NWCMFNIMUUMBGZ-UHFFFAOYSA-N 0.000 description 2
- RTKSHBXMWCKUDQ-UHFFFAOYSA-N 4-methoxy-3-methylbenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1C RTKSHBXMWCKUDQ-UHFFFAOYSA-N 0.000 description 2
- VFMHROFKHVJMRD-UHFFFAOYSA-N 5-chloro-2-phenyl-1-benzofuran Chemical compound C=1C2=CC(Cl)=CC=C2OC=1C1=CC=CC=C1 VFMHROFKHVJMRD-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- OIJMMFLFMZRDAO-UHFFFAOYSA-N [2-(4-chlorophenyl)-1-benzofuran-3-yl]-(4-hydroxyphenyl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C1=C(C=2C=CC(Cl)=CC=2)OC2=CC=CC=C12 OIJMMFLFMZRDAO-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 2
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical class CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- ZSBIMTDWIGWJPW-UHFFFAOYSA-N methyl 3-chloro-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C(Cl)=C1 ZSBIMTDWIGWJPW-UHFFFAOYSA-N 0.000 description 2
- PINQDVFQCCFACD-UHFFFAOYSA-N methyl 3-chloro-4-methoxybenzoate Chemical compound COC(=O)C1=CC=C(OC)C(Cl)=C1 PINQDVFQCCFACD-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- SATVIFGJTRRDQU-UHFFFAOYSA-N potassium hypochlorite Chemical compound [K+].Cl[O-] SATVIFGJTRRDQU-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- PNFMEGSMKIHDFZ-UHFFFAOYSA-N (2-Butylbenzofuran-3-yl)(4-hydroxy-3,5-diiodophenyl)ketone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(O)C(I)=C1 PNFMEGSMKIHDFZ-UHFFFAOYSA-N 0.000 description 1
- AQNNLGWKMDCSLD-UHFFFAOYSA-N (2-benzyl-1-benzofuran-3-yl)-(4-hydroxyphenyl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C(C1=CC=CC=C1O1)=C1CC1=CC=CC=C1 AQNNLGWKMDCSLD-UHFFFAOYSA-N 0.000 description 1
- DKICEZUJWFZAMX-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(2-chloro-4-methoxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(OC)C=C1Cl DKICEZUJWFZAMX-UHFFFAOYSA-N 0.000 description 1
- PCTLKBQOIAFIEL-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(2-methoxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=CC=C1OC PCTLKBQOIAFIEL-UHFFFAOYSA-N 0.000 description 1
- QSFSAJOAKXGLAD-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(4-chloro-2-methoxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1OC QSFSAJOAKXGLAD-UHFFFAOYSA-N 0.000 description 1
- LQLBLTBRQBNBBL-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-dimethylphenyl)methanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(C)=C(O)C(C)=C1 LQLBLTBRQBNBBL-UHFFFAOYSA-N 0.000 description 1
- DZDWJGHJHGVATA-UHFFFAOYSA-N (2-butyl-5-chloro-1-benzofuran-3-yl)-(4-hydroxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=C(Cl)C=C2C=1C(=O)C1=CC=C(O)C=C1 DZDWJGHJHGVATA-UHFFFAOYSA-N 0.000 description 1
- CPPZAMTVQXAEKC-UHFFFAOYSA-N (2-butyl-5-chloro-1-benzofuran-3-yl)-(4-methoxyphenyl)methanone Chemical compound CCCCC=1OC2=CC=C(Cl)C=C2C=1C(=O)C1=CC=C(OC)C=C1 CPPZAMTVQXAEKC-UHFFFAOYSA-N 0.000 description 1
- HJIAMFHSAAEUKR-UHFFFAOYSA-N (2-hydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=CC=C1C(=O)C1=CC=CC=C1 HJIAMFHSAAEUKR-UHFFFAOYSA-N 0.000 description 1
- YKTKSGMDYIJVFC-UHFFFAOYSA-N (3-ethyl-1-benzofuran-2-yl)-(4-hydroxyphenyl)methanone Chemical compound O1C2=CC=CC=C2C(CC)=C1C(=O)C1=CC=C(O)C=C1 YKTKSGMDYIJVFC-UHFFFAOYSA-N 0.000 description 1
- QGMAEAPQKFUJGO-UHFFFAOYSA-N (4-chlorophenyl)-(3-hydroxy-2,3-dihydro-1-benzofuran-2-yl)methanone Chemical compound O1C2=CC=CC=C2C(O)C1C(=O)C1=CC=C(Cl)C=C1 QGMAEAPQKFUJGO-UHFFFAOYSA-N 0.000 description 1
- DDMABCQEXXTERF-UHFFFAOYSA-N (4-cyano-2-methoxyphenyl) acetate Chemical compound COC1=CC(C#N)=CC=C1OC(C)=O DDMABCQEXXTERF-UHFFFAOYSA-N 0.000 description 1
- CJGXWABHYYJNJH-UHFFFAOYSA-N (4-cyanophenyl) acetate Chemical compound CC(=O)OC1=CC=C(C#N)C=C1 CJGXWABHYYJNJH-UHFFFAOYSA-N 0.000 description 1
- BCQDWIKXULTIHQ-UHFFFAOYSA-N (4-hydroxyphenyl)-(2-methyl-1-benzofuran-3-yl)methanone Chemical compound CC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 BCQDWIKXULTIHQ-UHFFFAOYSA-N 0.000 description 1
- RDWUDKIZLACHKY-UHFFFAOYSA-N (4-hydroxyphenyl)-(2-phenyl-1-benzofuran-3-yl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C1=C(C=2C=CC=CC=2)OC2=CC=CC=C12 RDWUDKIZLACHKY-UHFFFAOYSA-N 0.000 description 1
- WMWUMVPYUYDVIR-UHFFFAOYSA-N (4-hydroxyphenyl)-(2-propyl-1-benzofuran-3-yl)methanone Chemical compound CCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 WMWUMVPYUYDVIR-UHFFFAOYSA-N 0.000 description 1
- YOGKVKZIQYEPBU-UHFFFAOYSA-N (4-hydroxyphenyl)-(3-methyl-1-benzofuran-2-yl)methanone Chemical compound O1C2=CC=CC=C2C(C)=C1C(=O)C1=CC=C(O)C=C1 YOGKVKZIQYEPBU-UHFFFAOYSA-N 0.000 description 1
- FDAYIPBBOKRVMH-UHFFFAOYSA-N (4-hydroxyphenyl)-(3-phenyl-1-benzofuran-2-yl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C1=C(C=2C=CC=CC=2)C2=CC=CC=C2O1 FDAYIPBBOKRVMH-UHFFFAOYSA-N 0.000 description 1
- YHTKTSKKNRXRKB-UHFFFAOYSA-N (4-methoxyphenyl)-(2-methyl-1-benzofuran-3-yl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(C)OC2=CC=CC=C12 YHTKTSKKNRXRKB-UHFFFAOYSA-N 0.000 description 1
- GDBOCNHOGRNDJM-UHFFFAOYSA-N (4-methoxyphenyl)-(2-phenyl-1-benzofuran-3-yl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(C=2C=CC=CC=2)OC2=CC=CC=C12 GDBOCNHOGRNDJM-UHFFFAOYSA-N 0.000 description 1
- ZBEOERKLDHKFHH-UHFFFAOYSA-N (5-chloro-2-phenyl-1-benzofuran-3-yl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(C=2C=CC=CC=2)OC2=CC=C(Cl)C=C12 ZBEOERKLDHKFHH-UHFFFAOYSA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- ABXGMGUHGLQMAW-UHFFFAOYSA-N 1-[3-(trifluoromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C(F)(F)F)=C1 ABXGMGUHGLQMAW-UHFFFAOYSA-N 0.000 description 1
- WCNHJDAARSCDEU-UHFFFAOYSA-N 1-benzofuran-2-yl-(2-hydroxy-5-methylphenyl)methanone Chemical compound CC1=CC=C(O)C(C(=O)C=2OC3=CC=CC=C3C=2)=C1 WCNHJDAARSCDEU-UHFFFAOYSA-N 0.000 description 1
- ZKGOMWQUXAQPJO-UHFFFAOYSA-N 1-benzofuran-2-yl-(2-methoxyphenyl)methanone Chemical class COC1=CC=CC=C1C(=O)C1=CC2=CC=CC=C2O1 ZKGOMWQUXAQPJO-UHFFFAOYSA-N 0.000 description 1
- FCFPEBKXSNOPAA-UHFFFAOYSA-N 1-benzofuran-2-yl-(3-fluoro-4-hydroxyphenyl)methanone Chemical compound C1=C(F)C(O)=CC=C1C(=O)C1=CC2=CC=CC=C2O1 FCFPEBKXSNOPAA-UHFFFAOYSA-N 0.000 description 1
- MFJCKQFUMBQBDU-UHFFFAOYSA-N 1-benzofuran-2-yl-(4-hydroxyphenyl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C1=CC2=CC=CC=C2O1 MFJCKQFUMBQBDU-UHFFFAOYSA-N 0.000 description 1
- VPVXOXQYVCWECX-UHFFFAOYSA-N 1-benzofuran-2-yl-(4-nitrophenyl)methanol Chemical compound C=1C2=CC=CC=C2OC=1C(O)C1=CC=C([N+]([O-])=O)C=C1 VPVXOXQYVCWECX-UHFFFAOYSA-N 0.000 description 1
- OCERGTIJQFUKIC-UHFFFAOYSA-N 1-benzofuran-2-yl-[3-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC(C(=O)C=2OC3=CC=CC=C3C=2)=C1 OCERGTIJQFUKIC-UHFFFAOYSA-N 0.000 description 1
- FPYFMAXQPGUPEF-UHFFFAOYSA-N 1-benzofuran-3-yl-(4-hydroxyphenyl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C1=COC2=CC=CC=C12 FPYFMAXQPGUPEF-UHFFFAOYSA-N 0.000 description 1
- AQDRSCNQICSNAG-UHFFFAOYSA-N 1-benzofuran-3-yl-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=COC2=CC=CC=C12 AQDRSCNQICSNAG-UHFFFAOYSA-N 0.000 description 1
- YTKRILODNOEEPX-UHFFFAOYSA-N 1-chlorobut-2-ene Chemical compound CC=CCCl YTKRILODNOEEPX-UHFFFAOYSA-N 0.000 description 1
- JOUOQPWPDONKKS-UHFFFAOYSA-N 1-ethynyl-3-nitrobenzene Chemical group [O-][N+](=O)C1=CC=CC(C#C)=C1 JOUOQPWPDONKKS-UHFFFAOYSA-N 0.000 description 1
- YIYBRXKMQFDHSM-UHFFFAOYSA-N 2,2'-Dihydroxybenzophenone Chemical compound OC1=CC=CC=C1C(=O)C1=CC=CC=C1O YIYBRXKMQFDHSM-UHFFFAOYSA-N 0.000 description 1
- PRWRIKBNUNAGTF-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-benzofuran Chemical compound C1=CC(Cl)=CC=C1C1=CC2=CC=CC=C2O1 PRWRIKBNUNAGTF-UHFFFAOYSA-N 0.000 description 1
- LTVNYBFQRYQEJU-UHFFFAOYSA-N 2-(chloromethyl)but-1-ene Chemical compound CCC(=C)CCl LTVNYBFQRYQEJU-UHFFFAOYSA-N 0.000 description 1
- GBGPVUAOTCNZPT-UHFFFAOYSA-N 2-Methylcumarone Chemical compound C1=CC=C2OC(C)=CC2=C1 GBGPVUAOTCNZPT-UHFFFAOYSA-N 0.000 description 1
- CPTZLEUOIGFXGS-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-1-benzofuran Chemical compound C1=CC(Cl)=CC=C1CC1=CC2=CC=CC=C2O1 CPTZLEUOIGFXGS-UHFFFAOYSA-N 0.000 description 1
- PQGBNQKWXXRPFN-UHFFFAOYSA-N 2-[(4-ethoxyphenyl)methyl]-1-benzofuran Chemical compound C1=CC(OCC)=CC=C1CC1=CC2=CC=CC=C2O1 PQGBNQKWXXRPFN-UHFFFAOYSA-N 0.000 description 1
- BPNQEUKXLYMIKP-UHFFFAOYSA-N 2-[chloro(phenyl)methyl]-1-benzofuran Chemical compound C=1C2=CC=CC=C2OC=1C(Cl)C1=CC=CC=C1 BPNQEUKXLYMIKP-UHFFFAOYSA-N 0.000 description 1
- BQOZCKYZFXUPCI-UHFFFAOYSA-N 2-[chloro-(4-nitrophenyl)methyl]-1-benzofuran Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(Cl)C1=CC2=CC=CC=C2O1 BQOZCKYZFXUPCI-UHFFFAOYSA-N 0.000 description 1
- RHYXPYYKENPZHB-UHFFFAOYSA-N 2-benzyl-1-benzofuran Chemical compound C=1C2=CC=CC=C2OC=1CC1=CC=CC=C1 RHYXPYYKENPZHB-UHFFFAOYSA-N 0.000 description 1
- XQJAHBHCLXUGEP-UHFFFAOYSA-N 2-bromo-1-(4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CBr)C=C1 XQJAHBHCLXUGEP-UHFFFAOYSA-N 0.000 description 1
- MBUPVGIGAMCMBT-UHFFFAOYSA-N 2-bromo-1-(4-nitrophenyl)ethanone Chemical compound [O-][N+](=O)C1=CC=C(C(=O)CBr)C=C1 MBUPVGIGAMCMBT-UHFFFAOYSA-N 0.000 description 1
- ZIYRDJLAJYTELF-UHFFFAOYSA-N 2-bromo-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1Br ZIYRDJLAJYTELF-UHFFFAOYSA-N 0.000 description 1
- OWSIEZFWRYDJLS-UHFFFAOYSA-N 2-butyl-4-methoxy-1-benzofuran Chemical compound C1=CC=C2OC(CCCC)=CC2=C1OC OWSIEZFWRYDJLS-UHFFFAOYSA-N 0.000 description 1
- AKUKSMDUSUHLOB-UHFFFAOYSA-N 2-butyl-5-methoxy-1-benzofuran Chemical compound COC1=CC=C2OC(CCCC)=CC2=C1 AKUKSMDUSUHLOB-UHFFFAOYSA-N 0.000 description 1
- IBANGHTVBPZCHF-UHFFFAOYSA-N 2-chloro-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(Cl)=C1 IBANGHTVBPZCHF-UHFFFAOYSA-N 0.000 description 1
- SYAIPNCFYHEQMA-UHFFFAOYSA-N 2-chloro-4-methoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C(Cl)=C1 SYAIPNCFYHEQMA-UHFFFAOYSA-N 0.000 description 1
- DCUBVYSJOUCQNJ-UHFFFAOYSA-N 2-ethyl-5-[(2-methylpropan-2-yl)oxy]-1-benzofuran Chemical compound CC(C)(C)OC1=CC=C2OC(CC)=CC2=C1 DCUBVYSJOUCQNJ-UHFFFAOYSA-N 0.000 description 1
- KQDJTBPASNJQFQ-UHFFFAOYSA-N 2-iodophenol Chemical compound OC1=CC=CC=C1I KQDJTBPASNJQFQ-UHFFFAOYSA-N 0.000 description 1
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 1
- YVYWZIRNUCLRDP-UHFFFAOYSA-N 2-phenyl-7-(trifluoromethyl)-1-benzofuran Chemical compound O1C=2C(C(F)(F)F)=CC=CC=2C=C1C1=CC=CC=C1 YVYWZIRNUCLRDP-UHFFFAOYSA-N 0.000 description 1
- GEVKGFRTXNJNKK-UHFFFAOYSA-N 3-chloropent-1-ene Chemical compound CCC(Cl)C=C GEVKGFRTXNJNKK-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- UFEYMXHWIHFRBX-UHFFFAOYSA-N 4-chloro-2-methoxybenzoic acid Chemical compound COC1=CC(Cl)=CC=C1C(O)=O UFEYMXHWIHFRBX-UHFFFAOYSA-N 0.000 description 1
- OKEFBVALFLRAFV-UHFFFAOYSA-N 4-chloro-2-methoxybenzoyl chloride Chemical compound COC1=CC(Cl)=CC=C1C(Cl)=O OKEFBVALFLRAFV-UHFFFAOYSA-N 0.000 description 1
- NVSLDNSTGOKOJF-UHFFFAOYSA-N 4-methoxy-3,5-dimethylbenzoyl chloride Chemical compound COC1=C(C)C=C(C(Cl)=O)C=C1C NVSLDNSTGOKOJF-UHFFFAOYSA-N 0.000 description 1
- DNMUMZLKDOZMEY-UHFFFAOYSA-N 4-methoxy-3-methylbenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1C DNMUMZLKDOZMEY-UHFFFAOYSA-N 0.000 description 1
- IOOGOHRKXRMUEQ-UHFFFAOYSA-N 4-methyl-1-benzofuran Chemical compound CC1=CC=CC2=C1C=CO2 IOOGOHRKXRMUEQ-UHFFFAOYSA-N 0.000 description 1
- AYOVPQORFBWFNO-UHFFFAOYSA-N 5-bromo-1-benzofuran Chemical compound BrC1=CC=C2OC=CC2=C1 AYOVPQORFBWFNO-UHFFFAOYSA-N 0.000 description 1
- QPTFSRLJKIACCB-UHFFFAOYSA-N 5-bromo-2-(4-bromophenyl)-1-benzofuran Chemical compound C1=CC(Br)=CC=C1C1=CC2=CC(Br)=CC=C2O1 QPTFSRLJKIACCB-UHFFFAOYSA-N 0.000 description 1
- AKSTZTXWHQYVDW-UHFFFAOYSA-N 5-chloro-2-ethyl-1-benzofuran Chemical compound ClC1=CC=C2OC(CC)=CC2=C1 AKSTZTXWHQYVDW-UHFFFAOYSA-N 0.000 description 1
- ZJBGVUBFQCFOSR-UHFFFAOYSA-N 5-ethyl-1-benzofuran Chemical compound CCC1=CC=C2OC=CC2=C1 ZJBGVUBFQCFOSR-UHFFFAOYSA-N 0.000 description 1
- KCZQNAOFWQGLCN-UHFFFAOYSA-N 5-methyl-1-benzofuran Chemical compound CC1=CC=C2OC=CC2=C1 KCZQNAOFWQGLCN-UHFFFAOYSA-N 0.000 description 1
- BKBDOWJPNZYBSO-UHFFFAOYSA-N 6-chloro-1-benzofuran Chemical compound ClC1=CC=C2C=COC2=C1 BKBDOWJPNZYBSO-UHFFFAOYSA-N 0.000 description 1
- AROWSPBDKGWJNQ-UHFFFAOYSA-N 7-chloro-1-benzofuran Chemical compound ClC1=CC=CC2=C1OC=C2 AROWSPBDKGWJNQ-UHFFFAOYSA-N 0.000 description 1
- FBLOWVGGTUOINW-UHFFFAOYSA-N 7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-yl-(3-propoxy-1-benzofuran-2-yl)methanone Chemical compound C(CC)OC1=C(OC2=C1C=CC=C2)C(C1=C2C(=CC=C1)O2)=O FBLOWVGGTUOINW-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical compound C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 101001022148 Homo sapiens Furin Proteins 0.000 description 1
- 101001128694 Homo sapiens Neuroendocrine convertase 1 Proteins 0.000 description 1
- 101000601394 Homo sapiens Neuroendocrine convertase 2 Proteins 0.000 description 1
- 101001072067 Homo sapiens Proprotein convertase subtilisin/kexin type 4 Proteins 0.000 description 1
- 101000828971 Homo sapiens Signal peptidase complex subunit 3 Proteins 0.000 description 1
- 101000979222 Hydra vulgaris PC3-like endoprotease variant A Proteins 0.000 description 1
- 101000979221 Hydra vulgaris PC3-like endoprotease variant B Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100032132 Neuroendocrine convertase 1 Human genes 0.000 description 1
- 102100037732 Neuroendocrine convertase 2 Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 108010022052 Proprotein Convertase 5 Proteins 0.000 description 1
- 102100036371 Proprotein convertase subtilisin/kexin type 4 Human genes 0.000 description 1
- 102100036365 Proprotein convertase subtilisin/kexin type 5 Human genes 0.000 description 1
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 1
- 101710180552 Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 1
- 102100038950 Proprotein convertase subtilisin/kexin type 7 Human genes 0.000 description 1
- 101710180647 Proprotein convertase subtilisin/kexin type 7 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- HSOBBBDWGHUTIG-UHFFFAOYSA-N [2-(3-aminophenyl)-1-benzofuran-3-yl]-(4-hydroxyphenyl)methanone Chemical compound NC1=CC=CC(C2=C(C3=CC=CC=C3O2)C(=O)C=2C=CC(O)=CC=2)=C1 HSOBBBDWGHUTIG-UHFFFAOYSA-N 0.000 description 1
- MTVIMVWZDJBJFM-UHFFFAOYSA-N [2-(4-chlorophenyl)-1-benzofuran-3-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(C=2C=CC(Cl)=CC=2)OC2=CC=CC=C12 MTVIMVWZDJBJFM-UHFFFAOYSA-N 0.000 description 1
- WMKQXKIPZOEOGT-UHFFFAOYSA-N [2-[(4-chlorophenyl)methyl]-1-benzofuran-3-yl]-(4-hydroxyphenyl)methanone Chemical compound C1=CC(O)=CC=C1C(=O)C(C1=CC=CC=C1O1)=C1CC1=CC=C(Cl)C=C1 WMKQXKIPZOEOGT-UHFFFAOYSA-N 0.000 description 1
- FJMPJNDWGKXRQJ-UHFFFAOYSA-N [2-[(4-ethoxyphenyl)methyl]-1-benzofuran-3-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OCC)=CC=C1CC1=C(C(=O)C=2C=CC(OC)=CC=2)C2=CC=CC=C2O1 FJMPJNDWGKXRQJ-UHFFFAOYSA-N 0.000 description 1
- WHDFOZQZLGETCC-UHFFFAOYSA-N [5-bromo-2-(4-bromophenyl)-1-benzofuran-3-yl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=C(C=2C=CC(Br)=CC=2)OC2=CC=C(Br)C=C12 WHDFOZQZLGETCC-UHFFFAOYSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- VEFXTGTZJOWDOF-UHFFFAOYSA-N benzene;hydrate Chemical compound O.C1=CC=CC=C1 VEFXTGTZJOWDOF-UHFFFAOYSA-N 0.000 description 1
- CZCHIEJNWPNBDE-UHFFFAOYSA-N benziodarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(O)C(I)=C1 CZCHIEJNWPNBDE-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- ZLYFWIZGRHGKMM-UHFFFAOYSA-N bis(1-benzofuran-2-yl)methanone Chemical compound C1=CC=C2OC(C(C=3OC4=CC=CC=C4C=3)=O)=CC2=C1 ZLYFWIZGRHGKMM-UHFFFAOYSA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical class BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003152 propanolamines Chemical class 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
Definitions
- This invention relates to new substituted benzofurans which have useful pharmacological activity. More specifically, the compounds of this invention have coronary vasodilator activity and are useful in the treatment of angina pectoris. In addition, these compounds may be useful as hypotensive agents.
- R 1 is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl
- R 2 is hydrogen, lower alkyl or phenyl(CH 2 ) n where n is 0 or 1 and the phenyl moiety is optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, halogen, NH 2 , NH(lower alkyl) or N(lower alkyl) 2 ;
- R 3 is ##SPC2##
- R 4 is hydrogen, halogen, lower alkyl or lower alkoxy
- n 1 or 2;
- R 5 , r 6 and R 7 are hydrogen or one of R 5 , R 6 and R 7 is methyl or ethyl;
- R 8 is hydrogen or lower alkanoyl
- R 9 is NH(lower alkyl), N(lower alkyl) 2 , NH(benzyl), N(lower alkanoyl)(lower alkyl), piperidino, pyrrolidino, morpholino or succinimido.
- lower alkyl and lower alkoxy denote groups having from one to four carbon atoms and lower alkanoyl denotes groups having from two to four carbon atoms.
- Preferred compounds of this invention are represented by Formula I in which R 2 is hydrogen, lower alkyl or phenyl(CH 2 ) n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoromethyl or chloro, R 5 , R 7 and R 8 are hydrogen, R 6 is hydrogen or methyl and R 9 is NH(isopropyl) or NH(t-butyl).
- R 1 is hydrogen or chloro in the 5-position
- R 2 is hydrogen, lower alkyl or phenyl(CH 2 ) n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoromethyl or chloro
- R 4 is hydrogen or halogen
- m is 1
- R 5 , R 6 , R 7 and R 8 are hydrogen and R 9 is NH(isopropyl) or NH(t-butyl).
- R 1 is hydrogen
- R 2 is hydrogen, lower alkyl or phenyl(CH 2 ) n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoromethyl or chloro
- R 3 is ##SPC3##
- R 4 is hydrogen or chloro, m is 1 and R 9 is NH(isopropyl) or NH(t-butyl).
- the compounds of this invention may exist as optical isomers due to the asymmetric carbon atom in the side chain of the acyl group. All of the isomers, including separated isomers and mixtures thereof, are included within the scope of this invention.
- R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and m are defined as above and R 9 ' is NH(lower alkyl), N(lower alkyl) 2 , NH(benzyl), piperidino, pyrrolidino, morpholino or succinimido.
- a hydroxyphenyl benzofuranyl ketone of Formula II is converted to the epoxy intermediate III which is then opened by reaction with an appropriate amine (R 9 'H).
- R 5 , R 6 and R 7 are hydrogen
- the epoxy intermediates of Formula III are prepared by reaction of a compound of Formula II with an epihalohydrin such as epichlorohydrin or epibromohydrin in the presence of a base such as sodium hydroxide or potassium carbonate in a solvent such as water, ethanol or acetone.
- R 5 , R 6 and R 7 are methyl or ethyl
- the corresponding compounds of Formula III are prepared by reaction of a hydroxyphenyl benzofuranyl ketone with a chloroalkene to give an alkenyloxyphenyl benzofuranyl ketone which is then epoxidized with m-chloroperbenzoic acid.
- the ring opening of the epoxy intermediates of Formula III is preferably carried out in a minimum amount of a solvent such as ethanol or with excess amine as solvent in a Parr pressure bomb at from about 25° to about 150°C. for from one to about 48 hours.
- a solvent such as ethanol or with excess amine as solvent in a Parr pressure bomb at from about 25° to about 150°C. for from one to about 48 hours.
- the product propanolamines are isolated and purified as such by standard techniques including solvent extraction, crystallization and chromatographic methods or as the corresponding acid addition salts which are formed with organic and inorganic acids according to methods known to the art.
- a solution of the amine in ether or an alcohol such as methanol or ethanol is treated with a solution of an organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or in an aqueous immiscible solvent, such as ether or chloroform, with the desired salt separating directly.
- organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, succinic, hexamic, oxalic, bismethylenesalicyclic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the 8-halotheophyllines, for example, 8-bromotheophylline.
- inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
- these salts may also be prepared by the classical method of double decomposition of appropriate salts which is well known to the art.
- the salts may be purified by the standard methods described above.
- the ratio of III and IV is variable and depends on the nature of R 1 , R 2 and R 4 , m, their relative positions and the base employed in the reaction. III and IV are separated by standard wet or dry column chromatographic methods.
- the compounds of Formula IV may be converted to the corresponding epoxy intermediates of Formula III by stirring a solution of IV in aqueous dioxane containing a base such as sodium hydroxide for from one to about 12 hours at about 25° to about 100°C.; or may be reacted with an amine as previously described to give the corresponding compounds of Formula I directly.
- a hydroxybenzoic acid is methylated by standard methods, for example with dimethyl sulfate, converted to the corresponding acid chloride with thionyl chloride and subsequently used to acylate a benzofuran nucleus by standard procedures, for example in the presence of stannic chloride in a solvent such as methylene chloride or carbon disulfide.
- the methoxyphenyl benzofuranyl ketones are demethylated by known methods, for example by use of pyridine hydrochloride or boron tribromide.
- hydroxyphenyl benzofuranyl ketone starting materials are prepared by addition of a methoxyphenyl magnesium halide to a 3-cyanobenzofuran followed by hydrolysis and subsequent demethylation as previously described.
- benzofuran nuclei used as starting materials in Scheme Ii are either known to the art or are prepared by one of the general methods for the synthesis of benzofurans described by Buu-Hoi et al., supra, Tanaka, J. Amer. Chem. Soc. 73:872 (1951), Bisagni et al., J. Chem. Soc. 3688 (1955), Grinev et al., Zhur. Obshchei Khim. 27:1087 (1957) and Castro et al., J. Org. Chem. 28:3313 (1963), 31:4071(1966), in Rodd, Chemistry of Carbon Compounds Vol. IV-A, 168-191 and in French Patent 1,537,206.
- the compounds of Formula I in which R 4 is bromine, m is 2, R 8 is hydrogen and R 9 is R 9 ' as defined above may also be prepared by treatment of the corresponding hydroxyphenyl benzofuranyl ketones where R 4 is hydrogen with bromine in acetic acid followed by epoxide formation and subsequent ring opening with R 9 'H.
- treatment of the hydroxyphenyl benzofuranyl ketones where R 4 is hydrogen with N-bromosuccinimide in dimethylformamide gives the compounds of Formula II where R 4 is bromo and m is 1.
- the compounds of Formula II may be alternatively prepared from reaction of the hydroxyphenyl benzofuranyl ketones where R 4 is hydrogen with potassium hypochlorite in methanol and aqueous base.
- R 8 is lower alkanoyl and R 9 is N(lower alkanoyl)(lower alkyl)
- R 8 is hydrogen and R 9 is NH(lower alkyl) by conventional methods, for example, by reaction of the hydroxy compound with a lower alkanoic acid anhydride or a lower alkanoyl halide. Also formed in this reaction are the corresponding compounds of Formula I in which R 8 is lower alkanoyl and R 9 is NH(lower alkyl). These products are separated by standard chromatographic methods.
- a carotid artery is catheterized and connected to a Sanborn pressure transducer to measure arterial blood pressure.
- a femoral vein is also catheterized for administering a solution of the test compound or its salt and supplemental anesthesia.
- a left thoractomy is made at the fourth or fifth intercostal space, the lung is displaced, the pericardium is opened and the left circumflex coronary artery is isolated for measurement of coronary blood flow, a "snare" being placed around the artery distally to obtain zero flow.
- Coronary blood flow is measured with a Statham electromagnetic Flowmeter and Flo-Probe (MDS).
- R 6 is hydrogen or methyl and R 9 is NH(lower alkyl), N(lower alkyl) 2 or NH(benzyl) also inhibit or attenuate the chronotropic effect of isoproterenol-induced tachycardia upon administration to dogs at doses of from about 0.63 to about 5.0 mg./kg. i.v. Abad et al. [Acta Pharmacol. et Toxicol. 25:85 (1967)] have correlated the inhibition of isoproterenol-induced tachycardia to utility as an antianginal agent.
- compositions having coronary vasodilator activity in dosage unit form, comprising a pharmaceutical carrier and, in an amount sufficient to produce coronary vasodilation, a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof, and methods of producing coronary vasodilation by administering these compounds are also objects of this invention.
- the pharmacologically active compounds of this invention may be administered orally or parenterally in an amount to produce the desired activity.
- the compounds are administered in conventional dosage unit forms prepared by combining an appropriate dose of the compound with standard pharmaceutical carriers.
- the dosage units will contain the active medicament in an amount of from about 100 mg. to about 600 mg., preferably 150 mg. to 300 mg., per dosage unit.
- the pharmaceutical carrier employed may be, for example, either a solid or liquid.
- solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
- liquid carriers are syrup, peanut oil, olive oil, water and the like.
- the carrier or diluent can include any time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
- a wide variety of pharmaceutical forms can be employed.
- a solid carrier the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
- the amount of solid carrier will vary widely but preferably will be from about 25 mg. to about 1 g.
- a liquid carrier the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or an aqueous or nonaqueous liquid suspension.
- compositions are prepared by conventional techniques involving procedures such as mixing, granulating and compressing or variously mixing and dissolving the ingredients as appropriate to the desired composition.
- the method of producing coronary vasodilator activity in accordance with this invention comprises administering internally to an animal an effective amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof.
- the compound will preferably be administered in a dosage unit form as described above orally or parenterally, the oral route being preferred.
- equal doses will be administered one to two times daily with the daily dosage regimen being from about 200 mg. to about 1200 mg., preferably from about 300 mg. to about 600 mg., of the active medicament.
- acid addition salts may be converted to the corresponding free amines by treating a solution of the salt in water, a chloroform-water or a benzene-water mixture with 10% aqueous sodium hydroxide, sodium carbonate or sodium bicarbonate until basic followed by extraction of the amine into benzene or chloroform.
- Salts other than hydrochlorides may be converted to the corresponding hydrochloric acid salts by passing a solution of the salt in methanol or ethanol through an Amberlite IRA-401 chloride ion exchange column.
- the chlorohydrin product was dissolved in 10% aqueous dioxane containing an excess of one molar equivalent of sodium hydroxide and stirred at 25° for 2 hours to effect conversion to the epoxide, m.p. 61°-62°.
- the salt is dissolved in a minimum amount of water to which chloroform is added. While stirring, 10% aqueous sodium carbonate is added until the solution becomes distinctly basic (pH 9-11). The layers are separated, the aqueous phase is extracted repeatedly with chloroform and the combined extracts are washed with water, dried (MgSO 4 ) and concentrated to give the title compound.
- the title compound is also prepared by heating a solution of 2-n-butyl-3-[4'-(2-hydroxy-3-chloro)propoxybenzoyl] benzofuran (chlorohydrin product) in ethanol with isopropylamine as described above.
- reaction mixture was extracted with chloroform and the extracts were washed with water, dried (MgSO 4 ) and concentrated to give a mixture of 2-n-butyl-3-[3',5'-diiodo-4'-(2,3-epoxy)propoxybenzoyl] benzofuran and 2-n-butyl-3-[3',5'-diiodo-4'-(2-hydroxy-3-chloro)propoxybenzoyl]benzofuran which was separated by dry column chromatography on alumina with methylene chloride.
- the substituted benzofurans prepared above were converted to their hexamic acid salts by addition of a 10% solution of hexamic acid in ethanol to a solution of the amine in ethanol.
- Example 3 The title compound was prepared by substitution of t-butylamine in the procedure of Example 3 for piperidine.
- the corresponding hydrochloric acid salt was prepared as described in Example 1, m.p. 122°-123° (ethanol).
- 2-n-Butyl-3-(3'-chloro-4'-methoxybezoyl)benzofuran was prepared by acylation of 2-n-butylbenzofuran with 3-chloro-4-methoxybenzoic acid chloride as described in the procedure of Example 10.
- the subsequent steps of demethylation, epoxide formation and ring opening of the 2-n-butyl-3-[3'-chloro-4'-(2,3-epoxy)propoxybenzoyl]benzofuran to give the title compound were accomplished as previously described.
- 2-n-Butylbezofuran (5.7 g., 0.033 mol.) was acylated with 6.7 g. (0.033 mol.) of 2-chloro-4-methoxybenzoic acid chloride in the presence of 18 g. (0.07 mol.) of stannic chloride as described in the procedure of Example 10 to give 2-n-butyl-3-(2'-chloro-4'-methoxybenzoyl)benzofuran.
- the subsequent demethylation, epoxy compound formation and ring opening of the epoxide to give the title compound were carried out as previously described in Examples 9 and 7.
- the epoxy compound was heated with isopropylamine as described in the procedure of Example 7 to give the title compound.
- the epoxy compound was heated with isopropylamine as described in the procedure of Example 7 to give the title compound.
- the epoxy compound was heated with isopropylamine in ethanol as described in the procedure of Example 1 to give 2-n-butyl-3-[4'-(2-hydroxy-2-methyl-3-isopropylamino)propoxybenzoyl]benzofuran.
- 2-propyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran was prepared by treatment of 2-propyl-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin followed by opening of the epoxide function with isopropylamine as described in the procedure of Example 7.
- 2-Phenylbenzofuran (7.81 g., 0.040 mol.) was acylated with 7.0 g. (0.041 mol.) of anisoyl chloride according to the procedure described in Example 10 to give 2-phenyl-3-(4'-methoxybenzoyl)benzofuran.
- 2-phenyl-3-[3'-chloro-4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran was prepared by acylation of 2-phenylbenzofuran with 3-chloro-4-methoxybenzoic acid chloride followed by the synthetic sequence of demethylation, reaction with epichlorohydrin and treatment of the 2-phenyl-3-[3'-chloro-4'-(2,3-epoxy)propoxybenzoyl]benzofuran formed with isopropylamine as previously described.
- 5-bromo-2(p-bromophenyl)benzofuran is acylated with anisoyl chloride and the resulting 5-bromo-2-(4'-bromophenyl)-3-(4'-methoxybenzoyl)benzofuran is demethylated and the product treated with epichlorohydrin to give an epoxy compound which is subsequently opened with isopropylamine to give 5-bromo-2-(4'-bromophenyl)-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
- 2-n-Butyl-5-chlorobenzofuran (9.5 g., 0.046 mol.) was acylated with 8 g. (0.047 mol.) of anisoyl chloride as described in the procedure of Example 10 to give 2-n-butyl-5-chloro-3-(4'-methoxybenzoyl)benzofuran.
- Demethylation followed by reaction of the 2-n-butyl-5-chloro-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin and subsequent opening of the epoxy compound formed with isopropylamine was carried out as described in the procedures of Examples 9 and 7 to give the title compound.
- 2-n-butyl-3-[4'-(2-hydroxy-3-N-acetylisopropylamino)propoxybenzoyl]benzofuran was prepared by refluxing 4.9 g. (0.01 mol.) of 2-n-butyl-3-[4'-(2-acetoxy-3-N-acetylisopropylamino)propoxybenzoyl]benzofuran with 5 ml. of 10% aqueous sodium hydroxide in 20 ml. of water for 1 hour. After cooling, chloroform was added to the reaction mixture, the layers were separated and the organic phase was washed with water, dried (Na 2 SO 4 ) and concentrated in vacuo to give the desired product.
- the products are 2-n-butyl-3-[4'-(2-n-butyryloxy-3-N-n-butyrylisopropyl-amino)propoxybenzoyl]benzofuran, 2-n-butyl-3-[4'-(2-n-butyryloxy-3-isopropylamino)propoxybenzoyl]benzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-N-n-butyrylisopropylamino)-propoxybenzoyl]benzofuran.
- 3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-2-phenyl-7-trifluoromethylbenzofuran is obtained from substitution of an equivalent amount of 2-phenyl-7-trifluoromethylbenzofuran in the procedure of Example 10 for 2 -n-butylbenzofuran followed by the subsequent synthetic steps of demethylation, treatment with epichlorohydrin and heating the epoxy compound thus formed with isopropylamine.
- 2-(4'-Nitrobenzyl)benzofuran is acylated with anisoyl chloride as described in Example 10. Demethylation with pyridine hydrochloride as previously described gives 3-(4'-hydroxybenzoyl)-2-(4'-nitrobenzyl)benzofuran.
- 3-(4'-Hydroxybenzoyl)-2-(4'-nitrobenzyl)benzofuran (37.3 g., 0.1 mol.) is added in small portions to 56.4 g. (0.25 mol.) of stannous chloride dihydrate in 70 ml. of concentrated hydrochloric acid.
- the reaction mixture is heated at 50° for 3 hours, then stirred at 25° for 12 hours. Cooling (ice bath) enhances precipitation of the product salt which is collected by filtration and dissolved in water.
- the aqueous solution is made basic by addition of 10% aqueous sodium hydroxide and extracted with chloroform. The extracts are dried (MgSO 4 ) and concentrated to give 2-(4'-aminobenzyl)-3-(4'-hydroxybenzoyl)benzofuran.
- a solution of 20 g. (0.105 mol.) of cuprous iodide in 400 ml. of ammonium hydroxide is poured with stirring into a solution of 15.4 g. (0.105 mol.) of m-nitrophenylacetylene in 500 ml. of ethanol.
- the reaction mixture is left to stand at 25° for 30 minutes then it is filtered and the product washed five times each with water, ethanol and ether to give cuprous m-nitrophenylacetylide.
- 2-(3'-Aminophenyl)-3-(4'-hydroxybenzoyl)benzofuran is prepared by reduction of 3-(4'-hydroxybenzoyl)-2-(3'-nitrophenyl)benzofuran according to the procedure of Example 40. Reaction of this compound with epichlorohydrin followed by ring opening of the resultant epoxy compound with isopropylamine as previously described gives the title compound.
- 3-phenyl-2-(4'-methoxybenzoyl)benzofuran is demethylated and the resultant 2-(4'-hydroxybenzoyl)-3-phenylbenzofuran is reacted with epichlorohydrin followed by ring opening of the epoxy compound thus formed with isopropylamine to give 2-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-3-phenylbenzofuran.
- 2-(p-ethoxybenzyl)benzofuran is acylated and the 2-(4'-ethoxybenzyl)-3-(4'-methoxybenzoyl)benzofuran is demethylated, the product treated with epichlorohydrin and the resultant epoxy compound opened with isopropylamine to give 2-(4'-ethoxybenzyl)-3-[4'-(2-hydroxy3-isopropylamino)propoxybenzoyl]benzofuran.
- sucrose, calcium sulfate dihydrate and 2-n-butyl3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran are thoroughly mixed and granulated with 10% gelatin solution.
- the wet granules are screened, dried and then mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
- the ingredients are mixed and filled into a hard gelatin capsule.
- compositions prepared as in Examples 47 and 48 are administered orally to a subject in need of coronary vasodilator activity within the dose ranges given hereabove.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Pharmaceutical compositions and methods of producing coronary vasodilation by administering substituted benzofurans, for example 2-n-butyl-3-[4' -(2-hydroxy-3-isopropylamino)propoxybenzoyl] benzofuran.
Description
This application is a continuation-in-part of application Ser. No. 399,573, filed Sept. 21, 1973, now U.S. Pat. No. 3,880,891.
This invention relates to new substituted benzofurans which have useful pharmacological activity. More specifically, the compounds of this invention have coronary vasodilator activity and are useful in the treatment of angina pectoris. In addition, these compounds may be useful as hypotensive agents.
The compounds of this invention are represented by the following structural formula: ##SPC1##
Or a pharmaceutically acceptable acid addition salt thereof, in which:
R1 is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl;
R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, halogen, NH2, NH(lower alkyl) or N(lower alkyl)2 ;
R3 is ##SPC2##
R4 is hydrogen, halogen, lower alkyl or lower alkoxy;
m is 1 or 2;
R5, r6 and R7 are hydrogen or one of R5, R6 and R7 is methyl or ethyl;
R8 is hydrogen or lower alkanoyl; and
R9 is NH(lower alkyl), N(lower alkyl)2, NH(benzyl), N(lower alkanoyl)(lower alkyl), piperidino, pyrrolidino, morpholino or succinimido.
As used herein, the terms lower alkyl and lower alkoxy denote groups having from one to four carbon atoms and lower alkanoyl denotes groups having from two to four carbon atoms.
Preferred compounds of this invention are represented by Formula I in which R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoromethyl or chloro, R5, R7 and R8 are hydrogen, R6 is hydrogen or methyl and R9 is NH(isopropyl) or NH(t-butyl). Most preferred are those compounds in which R1 is hydrogen or chloro in the 5-position, R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoromethyl or chloro, R4 is hydrogen or halogen, m is 1, R5, R6, R7 and R8 are hydrogen and R9 is NH(isopropyl) or NH(t-butyl).
Advantageous compounds of this invention are represented by Formula I in which R1 is hydrogen, R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoromethyl or chloro, R3 is ##SPC3##
R4 is hydrogen or chloro, m is 1 and R9 is NH(isopropyl) or NH(t-butyl).
Particularly preferred are the compounds 2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran, 2-n-butyl-3-[3'-chloro-4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran, 2-n-butyl-3-[4'-chloro-2'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran and 2-(4'-chlorobenzyl)-3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl] benzofuran.
The compounds of this invention may exist as optical isomers due to the asymmetric carbon atom in the side chain of the acyl group. All of the isomers, including separated isomers and mixtures thereof, are included within the scope of this invention.
The compounds of Formula I in which R8 is hydrogen and R9 is NH(lower alkyl), N(lower alkyl)2, NH(benzyl), piperidino, pyrrolidino, morpholino or succinimide are prepared as shown in the following scheme: ##SPC4##
The terms R1, R2, R4, R5, R6, R7 and m are defined as above and R9 ' is NH(lower alkyl), N(lower alkyl)2, NH(benzyl), piperidino, pyrrolidino, morpholino or succinimido.
According to the above procedure, a hydroxyphenyl benzofuranyl ketone of Formula II is converted to the epoxy intermediate III which is then opened by reaction with an appropriate amine (R9 'H). When R5, R6 and R7 are hydrogen, the epoxy intermediates of Formula III are prepared by reaction of a compound of Formula II with an epihalohydrin such as epichlorohydrin or epibromohydrin in the presence of a base such as sodium hydroxide or potassium carbonate in a solvent such as water, ethanol or acetone. When one of R5, R6 and R7 is methyl or ethyl, the corresponding compounds of Formula III are prepared by reaction of a hydroxyphenyl benzofuranyl ketone with a chloroalkene to give an alkenyloxyphenyl benzofuranyl ketone which is then epoxidized with m-chloroperbenzoic acid.
The ring opening of the epoxy intermediates of Formula III is preferably carried out in a minimum amount of a solvent such as ethanol or with excess amine as solvent in a Parr pressure bomb at from about 25° to about 150°C. for from one to about 48 hours.
The product propanolamines are isolated and purified as such by standard techniques including solvent extraction, crystallization and chromatographic methods or as the corresponding acid addition salts which are formed with organic and inorganic acids according to methods known to the art. Thus, a solution of the amine in ether or an alcohol such as methanol or ethanol is treated with a solution of an organic or inorganic acid in an aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling or in an aqueous immiscible solvent, such as ether or chloroform, with the desired salt separating directly. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, succinic, hexamic, oxalic, bismethylenesalicyclic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the 8-halotheophyllines, for example, 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the classical method of double decomposition of appropriate salts which is well known to the art. The salts may be purified by the standard methods described above.
Also formed in the reaction of II with epichlorohydrin is a compound of Formula IV: ##SPC5##
The ratio of III and IV is variable and depends on the nature of R1, R2 and R4, m, their relative positions and the base employed in the reaction. III and IV are separated by standard wet or dry column chromatographic methods. The compounds of Formula IV may be converted to the corresponding epoxy intermediates of Formula III by stirring a solution of IV in aqueous dioxane containing a base such as sodium hydroxide for from one to about 12 hours at about 25° to about 100°C.; or may be reacted with an amine as previously described to give the corresponding compounds of Formula I directly.
The hydroxyphenyl benzofuranyl ketone starting materials of Scheme I, in which R2 is in the 2-position and R3 is in the 3-position of the benzofuran nucleus (V) are either known to the art or are prepared as outlined below: ##SPC6##
According to Scheme II, a hydroxybenzoic acid is methylated by standard methods, for example with dimethyl sulfate, converted to the corresponding acid chloride with thionyl chloride and subsequently used to acylate a benzofuran nucleus by standard procedures, for example in the presence of stannic chloride in a solvent such as methylene chloride or carbon disulfide. The methoxyphenyl benzofuranyl ketones are demethylated by known methods, for example by use of pyridine hydrochloride or boron tribromide. These and other methods are described by Buu-hoi et al., J. Chem. Soc. 3693 (1955), 625 (1957), 2593 (1957), 173 (1964) and in Japanese Patent 2482/64.
Alternatively, the hydroxyphenyl benzofuranyl ketone starting materials are prepared by addition of a methoxyphenyl magnesium halide to a 3-cyanobenzofuran followed by hydrolysis and subsequent demethylation as previously described.
The benzofuran nuclei used as starting materials in Scheme Ii are either known to the art or are prepared by one of the general methods for the synthesis of benzofurans described by Buu-Hoi et al., supra, Tanaka, J. Amer. Chem. Soc. 73:872 (1951), Bisagni et al., J. Chem. Soc. 3688 (1955), Grinev et al., Zhur. Obshchei Khim. 27:1087 (1957) and Castro et al., J. Org. Chem. 28:3313 (1963), 31:4071(1966), in Rodd, Chemistry of Carbon Compounds Vol. IV-A, 168-191 and in French Patent 1,537,206.
To prepare the compounds of Formula I in which R2 is in the 3-position and R3 is in the 2-position of the benzofuran nucleus, the required hydroxyphenyl benzofuranyl ketone starting materials of Scheme I are either known to the art or are prepared by the method of Buu-Hoi et al., J. Chem. Soc. 3693 (1955) and 2593 (1957) shown in Scheme III: ##SPC7##
Reaction of a salicylic acid or an o-hydroxyphenyl ketone with a substituted α-bromoacetophenone in the presence of base followed by demethylation as described above gives the hydroxyphenyl benzofuranyl ketones of Formula VI.
The compounds of Formula I in which R4 is bromine, m is 2, R8 is hydrogen and R9 is R9 ' as defined above may also be prepared by treatment of the corresponding hydroxyphenyl benzofuranyl ketones where R4 is hydrogen with bromine in acetic acid followed by epoxide formation and subsequent ring opening with R9 'H. Similarly, treatment of the hydroxyphenyl benzofuranyl ketones where R4 is hydrogen with N-bromosuccinimide in dimethylformamide gives the compounds of Formula II where R4 is bromo and m is 1. When R4 is chloro and m is 2, the compounds of Formula II may be alternatively prepared from reaction of the hydroxyphenyl benzofuranyl ketones where R4 is hydrogen with potassium hypochlorite in methanol and aqueous base.
The compounds of this invention in which R8 is lower alkanoyl and R9 is N(lower alkanoyl)(lower alkyl) are prepared from the corresponding compounds of Formula I where R8 is hydrogen and R9 is NH(lower alkyl) by conventional methods, for example, by reaction of the hydroxy compound with a lower alkanoic acid anhydride or a lower alkanoyl halide. Also formed in this reaction are the corresponding compounds of Formula I in which R8 is lower alkanoyl and R9 is NH(lower alkyl). These products are separated by standard chromatographic methods. When R8 is hydrogen and R9 is N(lower alkyl)2, piperidino, pyrrolidino, morpholino or succinimido, treatment with a lower alkanoic acid anhydride or a lower alkanoyl halide yields the corresponding compounds of Formula I in which R8 is lower alkanoyl. Basic hydrolysis of the N,O-di-(lower alkanoyl) compounds of this invention give the corresponding compounds of Formula I in which R8 is hydrogen and R9 is N(lower alkanoyl)(lower alkyl).
The coronary vasodilator activity and hypotensive effects of the compounds represented by Formula I are demonstrated in dogs by an increase in coronary blood flow with concomitant decrease of mean arterial blood pressure upon intravenous administration of doses of from about 0.5 to about 5.0 mg./kg. These parameters are measured as follows:
Adult mongrel dogs (13-16 kg.) are pretreated with 2 mg./kg. s.c. of morphine sulfate followed in one hour by intravenous administration of 1-1.5 ml./kg. of an aqueous solution containing 1.5% chloralose and 20% urethane. Supplemental doses of morphine and chloralose-urethane are given to maintain an adequate and uniform depth of anesthesia.
A carotid artery is catheterized and connected to a Sanborn pressure transducer to measure arterial blood pressure. A femoral vein is also catheterized for administering a solution of the test compound or its salt and supplemental anesthesia. A left thoractomy is made at the fourth or fifth intercostal space, the lung is displaced, the pericardium is opened and the left circumflex coronary artery is isolated for measurement of coronary blood flow, a "snare" being placed around the artery distally to obtain zero flow. Coronary blood flow is measured with a Statham electromagnetic Flowmeter and Flo-Probe (MDS).
In addition, many of the compounds of this invention, for example those represented by Formula I in which R1 is hydrogen, R3 is ##SPC8##
R6 is hydrogen or methyl and R9 is NH(lower alkyl), N(lower alkyl)2 or NH(benzyl) also inhibit or attenuate the chronotropic effect of isoproterenol-induced tachycardia upon administration to dogs at doses of from about 0.63 to about 5.0 mg./kg. i.v. Abad et al. [Acta Pharmacol. et Toxicol. 25:85 (1967)] have correlated the inhibition of isoproterenol-induced tachycardia to utility as an antianginal agent.
Pharmaceutical compositions having coronary vasodilator activity, in dosage unit form, comprising a pharmaceutical carrier and, in an amount sufficient to produce coronary vasodilation, a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof, and methods of producing coronary vasodilation by administering these compounds are also objects of this invention.
The pharmacologically active compounds of this invention may be administered orally or parenterally in an amount to produce the desired activity.
Preferably, the compounds are administered in conventional dosage unit forms prepared by combining an appropriate dose of the compound with standard pharmaceutical carriers. The dosage units will contain the active medicament in an amount of from about 100 mg. to about 600 mg., preferably 150 mg. to 300 mg., per dosage unit.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent can include any time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg. to about 1 g. If a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or an aqueous or nonaqueous liquid suspension.
The pharmaceutical compositions are prepared by conventional techniques involving procedures such as mixing, granulating and compressing or variously mixing and dissolving the ingredients as appropriate to the desired composition.
The method of producing coronary vasodilator activity in accordance with this invention comprises administering internally to an animal an effective amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof. The compound will preferably be administered in a dosage unit form as described above orally or parenterally, the oral route being preferred. Advantageously, equal doses will be administered one to two times daily with the daily dosage regimen being from about 200 mg. to about 1200 mg., preferably from about 300 mg. to about 600 mg., of the active medicament. When the method described above is carried out, coronary vasodilation is produced.
One skilled in the art will recognize that in determining the amounts of the active medicament in the claimed compositions and used in the claimed methods, the activity of the particular medicament as well as the size of the host animal must be considered.
The following examples illustrate the invention but are not to be construed as limiting the scope thereof. Temperatures are in degrees Centigrade unless otherwise stated.
When formed, acid addition salts may be converted to the corresponding free amines by treating a solution of the salt in water, a chloroform-water or a benzene-water mixture with 10% aqueous sodium hydroxide, sodium carbonate or sodium bicarbonate until basic followed by extraction of the amine into benzene or chloroform. Salts other than hydrochlorides may be converted to the corresponding hydrochloric acid salts by passing a solution of the salt in methanol or ethanol through an Amberlite IRA-401 chloride ion exchange column.
To a solution of 8.7 g. (0.03 mol.) of 2-n-butyl-3-(4'-hydroxybenzoyl)benzofuran in 100 ml. of water containing 1.4 g. (0.035 mol.) of sodium hydroxide was added dropwise 4.0 g. (0.044 mol.) of epichlorohydrin. The reaction mixture was stirred and refluxed for one hour, then cooled and extracted with chloroform. The extracts were washed with water and a saturated aqueous solution of sodium chloride, dried (MgSo4) and concentrated to yield a mixture of 2-n-butyl-3-[4'-(2,3-epoxy)propoxybenzoyl]benzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-chloro)propoxybenzoyl]benzofuran which was separated by dry column chromatography on alumina with chloroform as the eluant.
The chlorohydrin product was dissolved in 10% aqueous dioxane containing an excess of one molar equivalent of sodium hydroxide and stirred at 25° for 2 hours to effect conversion to the epoxide, m.p. 61°-62°.
A solution of 1.5 g. (0.004 mol.) of 2-n-butyl-3-[4'-(2,3-epoxy)propoxybenzoyl] benzofuran and 25 ml. of isopropylamine in 20 ml. of ethanol was heated in a Parr pressure bomb for 12 hours at 120°. After cooling, the solvent and excess amine were removed in vacuo to give the title compound which was dissolved in ether and treated with an ethereal solution of hydrogen chloride until pH 2-4. The precipitated salt was collected and recrystallized from isopropanol-isopropyl ether to give the title compond as its hydrochloric acid salt, m.p. 123°-125°.
The salt is dissolved in a minimum amount of water to which chloroform is added. While stirring, 10% aqueous sodium carbonate is added until the solution becomes distinctly basic (pH 9-11). The layers are separated, the aqueous phase is extracted repeatedly with chloroform and the combined extracts are washed with water, dried (MgSO4) and concentrated to give the title compound.
The title compound is also prepared by heating a solution of 2-n-butyl-3-[4'-(2-hydroxy-3-chloro)propoxybenzoyl] benzofuran (chlorohydrin product) in ethanol with isopropylamine as described above.
A mixture of 10.8 g. (0.02 mol.) of 2-n-butyl-3-(3',5'-diiodo-4'-hydroxybenzoyl)benzofuran, 1 g. (0.025 mol.) of sodium hydroxide and 3 g. of epichlorohydrin in 100 ml. of water was stirred at 25° for 12 hours. The reaction mixture was extracted with chloroform and the extracts were washed with water, dried (MgSO4) and concentrated to give a mixture of 2-n-butyl-3-[3',5'-diiodo-4'-(2,3-epoxy)propoxybenzoyl] benzofuran and 2-n-butyl-3-[3',5'-diiodo-4'-(2-hydroxy-3-chloro)propoxybenzoyl]benzofuran which was separated by dry column chromatography on alumina with methylene chloride.
A solution of 1 g. (0.0017 mol.) of 2-n-butyl-3-[3',5'-diiodo-4'-(2,3-epoxy)propoxybenzoyl]benzofuran and 10 ml. of t-butylamine in 50 ml. of ethanol was stirred at 25° for 24 hours. The solvent and excess amine were removed in vacuo to give the title compound which was converted to its hydrochloric acid salt as described in Example 1.
A solution of 2-n-butyl-3-[4'-(2,3-epoxy)propoxybenzoyl] benzofuran and excess piperidine in ethanol was refluxed for 12 hours. Concentration in vacuo gave the title compound which was dissolved in ethanol and converted to its hydrochloric acid salt by the procedure described in Example 1, m.p. 131°-133° (ethanol-ether).
When pyrrolidine, morpholine or 30% aqueous methyl amine was substituted in the procedure of Example 3 for piperidine, there was obtained 2-n-butyl-3-[4'-(2-hydroxy-3-pyrrolidino)propoxybenzoyl]benzofuran, 2-n-butyl-3-[4'-(2-hydroxy-3-morpholino)propoxybenzoyl]benzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-methylamino)propoxybenzoyl]-benzofuran, respectively,
The substituted benzofurans prepared above were converted to their hexamic acid salts by addition of a 10% solution of hexamic acid in ethanol to a solution of the amine in ethanol.
The title compound was prepared by substitution of t-butylamine in the procedure of Example 3 for piperidine. The corresponding hydrochloric acid salt was prepared as described in Example 1, m.p. 122°-123° (ethanol).
A mixture of 8.0 g. (0.024 mol.) of 2-n-butyl-3-[4'-(2,3-epoxy)propoxybenzoyl] benzofuran and 2.5 g. (0.025 mol.) of succinimide in 100 ml. of ethanol containing 1 ml. of pyridine was refluxed with stirring for 22 hours. The reaction mixture was cooled to ambient temperature, then refrigerated for 12 hours. The precipitate was collected by filtration, washed with ethanol and ether and dried to give the title compound, m.p. 127°-130° (ethanol).
To a solution of 15 g. (0.051 mol.) of 2-n-butyl-3-(4'-hydroxybenzoyl)benzofuran in 150 ml. of 1:1 acetic acid-water was added dropwise a solution of 8.5 g. of bromine in 20 ml. of acetic acid. The reaction mixture was stirred at 25° for three hours, then it was filtered and the solid product was washed with water, aqueous sodium bisulfite, 5% aqueous sodium bicarbonate and again with water. The crude product was chromatographed on alumina with 2:1 chloroform-methanol as eluant to give 2-n-butyl-3-(3',5'-dibromo-4'-hydroxybenzoyl)benzofuran.
A mixture of 7 g. (0.014 mol.) of 2-n-butyl-3-(3',5'-dibromo-4'-hydroxybenzoyl)benzofuran, 1g. (0.025 mol.) of sodium hydroxide and 15 ml. of epichlorohydrin in 100 ml. of water was refluxed for one hour. After cooling, chloroform was added to the reaction mixture and the layers were separated. The organic phase was washed with water, dried (Na2 SO4) and concentrated to give a mixture of 2-n-butyl-3-[3',5'-dibromo-4'-(2,3-epoxy)propoxybenzoyl]benzofuran and 2-n-butyl-3-[3',5'-dibromo-4'-(2-hydroxy-3-chloro)propoxybenzoyl]benzofuran. The mixture was separated by dry column chromatography on alumina with chloroform as eluant and the chlorohydrin was converted to additional epoxy compound as described in Example 1.
2-n-Butyl-3-[3',5'-dibromo-4'-(2,3-epoxy)propoxybenzoyl]benzofuran (3.0 g., 0.006 mol.) was heated with 25 ml. of isopropylamine in a Parr bomb at 80° for two hours. After cooling, the reaction mixture was concentrated in vacuo and the residue was chromatographed on alumina with chloroform as eluant to give the title compound, m.p. 112°-113° (ether).
A mixture of 10.0 g. (0.034 mol.) of 2-n-butyl-3-(4'-hydroxybenzoyl)benzofuran and 6.1 g. (0.034 mol.) of N-bromosuccinimide in 150 ml. of damp dimethylformamide was refluxed for 12 hours. The reaction mixture was poured into water and extracted with chloroform. The extracts were washed repeatedly with water, then dried (Na2 SO4) and concentrated to give 2-n-butyl-3-(3'-bromo-4'-hydroxybenzoyl)-benzofuran.
The epoxide (4 g., 0.009 mol.) was heated with 20 ml. of isopropylamine at 80° for 2.5 hours as described in Examples 1 and 7 to give the title compound.
A solution of 11.5 g. (0.07 mol.) of 3-methyl-4-methoxybenzoic acid and 10.7 g. (0.09 mol.) of thionyl chloride in 60 ml. of methylene chloride was refluxed on a steam bath for two hours. Concentration in vacuo and distillation of the residue gave 3-methyl-4-methoxybenzoic acid chloride, m.p. 37°-39°.
To a cooled, stirred solution of 10.8 g. (0.058 mol.) of 3-methyl-4-methoxybenzoic acid chloride and 9.4 g. (0.054 mol.) of 2-n-butylbenzofuran in 40 ml. of carbon disulfide was added dropwise over a 20 minute interval 28.2 g. (0.108 mol.) of stannic chloride. After addition, the reaction mixture was warmed to ambient temperature and stirred for two hours. The mixture was then poured onto 100 ml. of ice-water and stirred for one hour. The solvent was removed, the product extracted into chloroform and the extracts were washed with water, dried (Na2 SO4) and concentrated in vacuo to give 2-n-butyl-3-(3'-methyl-4'-methoxybenzoyl)benzofuran.
Opening of the epoxy compound with isopropylamine to give the title compound was accomplished as described in Example 7.
To a cooled (ice bath) mixture of 9.4 g. (0.054 mol.) of 2-n-butylbenzofuran and 11.5 g. (0.058 mol.) of 3,5-dimethyl-4-methoxybenzoic acid chloride in 100 ml. of methylene chloride was added dropwise 28.7 g. (0.11 mol.) of stannic chloride. The reaction mixture was allowed to warm to ambient temperature, then stirred for 2 hours. Water was slowly added to the mixture and it was stirred an additional 30 minutes. The layers were separated and the organic phase was washed with water until the washings were neutral, dried (MgSO4) and concentrated to give 2-n-butyl-3-(3',5'-dimethyl-4'-methoxybenzoyl)benzofuran.
A solution of 25 g. (0.14 mol.) of 3-chloro-4-hydroxybenzoic acid in 200 ml. of methanol containing 2 ml. of sulfuric acid was refluxed for 12 hours. After cooling, excess methanol was evaporated, water was added to the residue and it was made basic with 10% aqueous sodium hydroxide. The precipitate was collected, washed with water and dried in vacuo to give 3-chloro-4-hydroxybenzoic acid methyl ester, m.p. 105°-107°C.
To a cooled solution of 14.5 g. (0.078 mol.) of 3-chloro-4-hydroxybenzoic acid methyl ester and 4.0 g. (0.1 mol.) of sodium hydroxide in 100 ml. of water was dropwise added 9.8 g. (7.3 ml., 0.079 mol.) of dimethyl sulfate. The reaction mixture was refluxed for two hours. After cooling, ether was added and the layers were separated. The organic phase was washed with water, dilute sulfuric acid and water, dried (Na2 SO4) and concentrated in vacuo to give 3-chloro-4-methoxybenzoic acid methyl ester, m.p. 72°-74°.
A mixture of 10.4 g. (0.052 mol.) of 3-chloro-4-methoxybenzoic acid methyl ester and 3.5 g. (0.09 mol.) of sodium hydroxide in 150 ml. of water was refluxed for two hours. The reaction mixture was cooled and acidified with 10% aqueous hydrochloric acid to precipitate 3-chloro-4-methoxybenzoic acid, m.p. 199°-202°. The acid was refluxed with thionyl chloride as described in the procedure of Example 9 to give 3-chloro-4-methoxybenzoic acid chloride, m.p. 55°-57°.
2-n-Butyl-3-(3'-chloro-4'-methoxybezoyl)benzofuran was prepared by acylation of 2-n-butylbenzofuran with 3-chloro-4-methoxybenzoic acid chloride as described in the procedure of Example 10. The subsequent steps of demethylation, epoxide formation and ring opening of the 2-n-butyl-3-[3'-chloro-4'-(2,3-epoxy)propoxybenzoyl]benzofuran to give the title compound were accomplished as previously described.
Addition of an ethereal solution of oxalic acid to a solution of the title compound in ether gave the oxalic acid addition salt. The oxalate was converted to the hydrochloric acid salt by passage of a solution of 2-n-butyl-3-[3'-chloro-4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran oxalate in ethanol through an Amberlite IRA-401 chloride ion exchange column.
To a suspension of 56.6 g. of calcium hypochlorite in 225 ml. of warm water was added a solution of 39.6 g. of potassium carbonate and 11.3 g. of potassium hydroxide in 120 ml. of water. The reaction vessel was stoppered and vigorously shaken until the gel which initially formed became fluid. The solid material was removed by filtration and the filtrate of aqueous potassium hypochlorite (45.3 g., 0.35 mol.) was then added dropwise to a cooled (ice bath), stirred solution of 38.3 g. (0.13 mol.) of 2-n-butyl-3-(4'-hydroxybenzoyl)benzofuran in 200 ml. of methanol and 100 ml. of 5% aqueous sodium hydroxide. After addition the reaction mixture was refluxed for five minutes, then cooled and left to stand at 25° for 12 hours. The mixture was acidified by addition of an ethereal solution of hydrogen chloride, additional amounts of ether were added and the layers were separated. The organic phase was washed with water, dried (Na2 SO4) and concentrated in vacuo to yield 2-n-butyl-3-(3',5'-dichloro-4'-hydroxybenzoyl)benzofuran, m.p. 110°-114° (cyclohexane).
2-n-Butyl-3-(3',5'-dichloro-4'-hydroxybenzoyl)benzofuran was converted to the corresponding (2,3-epoxy)propoxybenzoylbenzofuran which was ring opened with isopropylamine as described in the procedure of Example 7 to give the title compound. The hydrochloric acid salt was formed as described in Example 1, m.p. 151°-153° (ethanol-ether).
2-Chloro-4-methoxybenzoic acid (6.2 g., 0.033 mol.) was converted to the corresponding acid chloride by heating with 75 ml. of thionyl chloride for two hours on a steam bath.
2-n-Butylbezofuran (5.7 g., 0.033 mol.) was acylated with 6.7 g. (0.033 mol.) of 2-chloro-4-methoxybenzoic acid chloride in the presence of 18 g. (0.07 mol.) of stannic chloride as described in the procedure of Example 10 to give 2-n-butyl-3-(2'-chloro-4'-methoxybenzoyl)benzofuran. The subsequent demethylation, epoxy compound formation and ring opening of the epoxide to give the title compound were carried out as previously described in Examples 9 and 7.
Acylation of 9.4 g. (0.054 mol.) of 2-n-butylbenzofuran with 9.9 g. (0.058 mol.) of m-anisoyl chloride according to the procedure described in Example 10 gave 2-n-butyl-3-(3'-methoxybenzoyl)benzofuran.
Demethylation of 2-n-butyl-3-(3'-methoxybenzoyl)benzofuran, followed by treatment of the resulting phenol with epichlorohydrin and subsequent epoxide ring opening with isopropylamine as described in Examples 9 and 7 gave the title compound.
Acylation of 9.4 g. (0.054 mol.) of 2-n-butylbenzofuran with 9.9 g. (0.058 mol.) of o-anisoyl chloride according to the procedure described in Example 10 gave 2-n-butyl-3-(2'-methoxybenzoyl)benzofuran which was demethylated with pyridine hydrochloride as previously described to give 2-n-butyl-3-(2'-hydroxybenzoyl)benzofuran.
A mixture of 7.5 g. (0.025 mol.) of 2-n-butyl-3-(2'-hydroxybenzoyl)benzofuran, 25 ml. of epichlorohydrin and 15.0 g. of potassium carbonate in 150 ml. of ethanol was refluxed for three hours. After cooling the reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was dissolved in water and the aqueous solution was extracted with methylene chloride. The extracts were combined, dried (Na2 SO4) and concentrated to give an oily residue that was chromatographed on alumina with chloroform as the eluant to give 2-n-butyl-3-[2'-(2,3-epoxy)propoxybenzoyl]benzofuran.
The epoxy compound was heated with isopropylamine as described in the procedure of Example 7 to give the title compound.
Acylation of 13.1 g. (0.075 mol.) of 2-n-butylbenzofuran with 15.4 g. (0.075 mol.) of 4-chloro-2-methoxybenzoic acid chloride, prepared from 4-chloro-2-methoxybenzoic acid and thionyl chloride as previously described, according to the procedure of Example 10 gave 2-n-butyl-3-(4'-chloro-2'-methoxybenzoyl)benzofuran. Demethylation as previously described gave 2-n-butyl-3-(4'-chloro-2'-hydroxybenzoyl)benzofuran.
A mixture of 2-n-butyl-3-(4'-chloro-2'-hydroxybenzoyl)benzofuran, 30 ml. of epichlorohydrin and 15 g. of potassium carbonate in 200 ml. of ethanol was refluxed for 18 hours. The reaction mixture was concentrated, water was added to the residue and the aqueous solution was extracted with methylene chloride. The extracts were washed with water, dried (MgSO4) and concentrated in vacuo to give 2-n-butyl-3-[4'-chloro-2'-(2,3-epoxy)propoxybenzoyl]benzofuran which was purified by dry column chromatography on alumina with chloroform as eluant.
The epoxy compound was heated with isopropylamine as described in the procedure of Example 7 to give the title compound.
To a solution of 30 g. (0.102 mol.) of 2-n-butyl-3-(4'-hydroxybenzoyl)benzofuran in 100 ml. of dioxane was added a solution of 4.5 g. (0.11 mol.) of sodium hydroxide in 10 ml. of water followed by 50 g. (0.552 mol.) of 3-chloro-2-methylpropene. The mixture was refluxed for 12 hours, then cooled and poured into 450 ml. of water. The aqueous mixture was extracted with ether and the extracts were combined, dried (MgSO4) and concentrated in vacuo to give 2-n-butyl-3-[4'-(2-methylprop-3-ene)oxybenzoyl]benzofuran which was purified by chromatography on alumina with chloroform as eluant.
To a cooled (ice bath), stirred solution of 10.4 g. (0.03 mol.) of the benzofuran olefin in 25 ml. of methylene chloride was added dropwise a solution of 7.52 g. (0.04 mol.) of m-chloroperbenzoic acid in 100 ml. of methylene chloride. The reaction mixture was allowed to warm to ambient temperature, then it was stirred for one hour. An aqueous solution of sodium sulfite was added to quench the reaction, the layers were separated and the organic layer was washed with 5% aqueous sodium bicarbonate, dried (MgSO4) and concentrated in vacuo to yield 2-n-butyl-3-[4'-(2-methyl-2,3-epoxy)propoxybenzoyl]benzofuran.
The epoxy compound was heated with isopropylamine in ethanol as described in the procedure of Example 1 to give 2-n-butyl-3-[4'-(2-hydroxy-2-methyl-3-isopropylamino)propoxybenzoyl]benzofuran.
By similar methods, substitution of an equivalent amount of 3-chloro-1-methylpropene in the above procedure followed by the synthetic steps of epoxidation and ring opening of the resultant epoxy compound with isopropylamine gives, ultimately, a mixture of 2-n-butyl-3-[4'-(2-hydroxy-1-methyl-3-isopropylamino) propoxybenzoyl]benzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-methyl-3-isopropylamino)propoxybenzoyl]benzofuran, which is separated by dry column chromatography on alumina.
2-[4'-(2,3-epoxy)propoxybenzoyl]benzofuran was prepared from 12.0 g. (0.050 mol.) of 2-(4'-hydroxybenzoyl)benzofuran, 3.0 g. of sodium hydroxide and 30 ml. of epichlorohydrin as described in the procedure of Example 7.
The epoxide ring was opened by heating with isopropylamine as described in Example 7 to give the title compound, m.p. 120°. Preparation of the hydrochloric acid salt was accomplished as described in Example 1, m.p. 158°-160° (ethanol-ether).
2-[3'-Chloro-4'-(2,3-epoxy)propoxybenzoyl]benzofuran was prepared from 2-(3'-chloro-4'-hydroxybenzoyl)benzofuran and epichlorohydrin according to the procedure described in Example 7.
The epoxide was opened by heating with isopropylamine as described in Example 7 to give the title compound, m.p. 117°-119° (benzene-hexane).
To a solution of the Grignard reagent prepared from 4.27 g. (0.14 g.-atom) of magnesium turnings and 31.0 g. (0.13 mol.) of 4-iodoanisole in 50 ml. of ether was added dropwise a solution of 10.0 g. (0.07 mol.) of 3-cyanobenzofuran in 150 ml. of ether. The reaction mixture was stirred at 25° for 17 hours, then 30 ml. of water was added followed by a mixture of 20 ml. of sulfuric acid and 40 ml. of water. Additional amounts of the acid solution were added to dissolve the precipitate that formed in the reaction mixture. The mixture was poured into 500 ml. of water and the aqueous solution was extracted with chloroform. The extracts were dried (MgSO4) and concentrated in vacuo to give 3-(4'-methoxybenzoyl)benzofuran which was purified by chromatography on alumina with chloroform, m.p. 89°-90° (hexane-benzene).
Demethylation with pyridine hydrochloride gave 3-(4'-hydroxybenzoyl)benzofuran which was reacted with epichlorohydrin as previously described in Example 7. The epoxide ring was opened with isopropylamine as described above to give the title compound which was purified by dry column chormatography on alumina with chloroform. The oxalic acid salt was prepared by the procedure of Example 11, m.p. 198°-200° (ethanol).
2-Methylbenzofuran (7.25 g., 0.055 mol.) was acylated with 15.7 g. (0.092 mol.) of anisoyl chloride according to the procedure described in Example 10 to give 2-methyl-3-(4'-methoxybenzoyl)benzofuran.
Demethylation, reaction of the 2-methyl-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin and subsequent epoxide ring opening with isopropylamine were accomplished as described in the procedures of Examples 9 and 7 to give the title compound which was purified by dry column chromatography on alumina with chloroform as eluant.
2-Ethyl-3-(4'-hydroxybenzoyl)benzofuran was treated with epichlorohydrin according to the procedure of Example 7 to give 2-ethyl-3-[4'-(2,3-epoxy)propoxybenzoyl]benzofuran which was subsequently heated with isopropylamine as previously described to give 2-ethyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran. The propanolamine was converted to the corresponding hydrochloric acid salt as described in Example 1, m.p. 82°-84° (ether-ethanol).
Similarly, 2-propyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran was prepared by treatment of 2-propyl-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin followed by opening of the epoxide function with isopropylamine as described in the procedure of Example 7.
2-Phenylbenzofuran (7.81 g., 0.040 mol.) was acylated with 7.0 g. (0.041 mol.) of anisoyl chloride according to the procedure described in Example 10 to give 2-phenyl-3-(4'-methoxybenzoyl)benzofuran.
Demethylation, reaction of the 2-phenyl-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin and subsequent epoxide ring opening with isopropylamine were accomplished as described in Examples 9 and 7 to give 2-phenyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran, m.p. 43°-50°.
In like manner, 2-phenyl-3-[3'-chloro-4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran was prepared by acylation of 2-phenylbenzofuran with 3-chloro-4-methoxybenzoic acid chloride followed by the synthetic sequence of demethylation, reaction with epichlorohydrin and treatment of the 2-phenyl-3-[3'-chloro-4'-(2,3-epoxy)propoxybenzoyl]benzofuran formed with isopropylamine as previously described.
Acylation of 20.1 g. (0.096 mol.) of 2-benzylbenzofuran with 17.5 g. (0.103 mol.) of anisoyl chloride according to the procedure of Example 10 gave 2-benzyl-3-(4∝-methoxybenzoyl)benzofuran which was demethylated with pyridine hydrochloride to give 2-benzyl-3-(4'-hydroxybenzoyl)bezofuran, m.p. 146°-149°.
Subsequent treatment of 2-benzyl-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin and ring opening of the epoxide thus formed with isopropylamine as previously described gave the title compound, m.p. 116°-119° (ethanol).
A mixture of 4.4 g. (0.015 mol.) of 2-n-butyl-3-(4'-hydroxybenzoyl)benzofuran, 4.66 g. (0.034 mol.) of epibromohydrin and 2.08 g. (0.015 mol.) of anhydrous potassium carbonate in 50 ml. of dry acetone was refluxed for 12 hours. The reaction mixture was cooled, filtered and the filtrate was concentrated in vacuo and distilled at reduced pressures to remove all traces of epibromohydrin from the product 2-n-butyl-3-[4'-(2,3-epoxy)propoxybenzoyl]benzofuran.
A solution of 5.14 g. (0.014 mol.) of 2-n-butyl-3-[4'-(2,3-epoxy)propoxybenzoyl]benzofuran and 2.14 g. (0.02 mol.) of benzylamine in 60 ml. of ethanol was refluxed for four hours. Concentration in vacuo gave the title compound which was converted to the corresponding hydrochloric acid salt as described in the procedure of Example 1, m.p. 168°-170°.
To a solution of 15.3 g. (0.125 mol.) of salicylaldehyde in 100 ml. of acetone was added 7.0 g. (0.125 mol.) of potassium hydroxide dissolved in a minimum amount of water. α-Bromo-p-chloroacetophenone (29.16 g., 0.125 mol.) was added dropwise with stirring and cooling (ice bath). After addition, the reaction mixture was stirred at 25° for 12 hours. The precipitate was collected by filtration, washed with water and combined with the residue remaining after concentration of the filtrate to give 2-(4'-chlorobenzoyl)-3-hydroxycoumaran which was immediately dehydrated in the presence of p-toluenesulfonic acid to yield 2-(4'-chlorobenzoyl)benzofuran.
Hydrazine hydrate (28.0 g., 0.5 mol.) was added to a solution of 42.0 g. (0.16 mol.) of 2-(4'-chlorobenzoyl)benzofuran in 400 ml. of ethanol and the reaction mixture was refluxed overnight. The solution was concentrated in vacuo, chloroform was added and the chloroform solution was washed with saturated aqueous sodium chloride, dried (MgSO4) and concentrated to yield the corresponding hydrazone. The hydrazone was dissolved in 100 ml. of dry dimethyl sulfoxide and added dropwise over a four hour interval to a slurry of 36.4 g. (0.32 mol.) of potassium t-butoxide in 100 ml. of dry dimethyl sulfoxide. The reaction mixture was poured into 500 ml. of water and the aqueous solution was extracted with chloroform. The extracts were washed with water, dried (MgSO4) and concentrated in vacuo to give 2-(4'-chlorobenzyl)benzofuran which was purified by chromatography on silica gel with carbon tetrachloride as eluant.
Acylation of 2-(chlorobenzyl)benzofuran with anisoyl chloride was accomplished as described in Example 10. Demethylation with pyridine hydrochloride as previously described followed by treatment of the 2-(4'-chlorobenzyl)-3-(4'-hydroxybenzoyl)benzofuran with epibromohydrin as described in the procedure of Example 25 and subsequent epoxide ring opening with isopropylamine according to the procedure of Example 7 gave the title compound. The corresponding hydrochloric acid salt was prepared as described in Example 1, m.p. 115°-119°.
To a solution of 24.8 g. (0.127 mol.) of m-trifluoromethylacetophenone in 20 ml. of anhydrous ether was added with cooling and stirring 0.15 g. of anhydrous aluminum chloride and 20.2 g. (0.127 mol.) of bromine. The reaction mixture was concentrated in vacuo and the residue was distilled to give α-bromo-m-trifluoromethylacetophenone, b.p. 135°-140° (20mm.).
Substitution of an equivalent amount of α-bromo-m-trifluoromethylacetophenone in the procedure of Example 26 for α-bromo-p-chloroacetophenone followed by treatment of the 2-(3'-trifluoromethylbenzoyl)benzofuran with hydrazine hydrate ultimately gave 2-(3'-trifluoromethylbenzyl)benzofuran, b.p. 195°-197° (25 mm.).
Acylation of 2-(3'-trifluoromethylbenzyl)benzofuran with anisoyl chloride was carried out as outlined in the procedure of Example 10. Demethylation with pyridine hydrochloride, treatment with epichlorohydrin and subsequent epoxide ring opening with isopropylamine were accomplished as described in the procedures of Examples 9 and 7 to give the title compound.
When 2-(4'-chlorophenyl)benzofuran was acylated with anisoyl chloride was described in the procedure of Example 10 and the resulting 2-(4'-chlorophenyl)-3-(4'-methoxybenzoyl)benzofuran was demethylated with pyridine hydrochloride as previously described, 2-(4'-chlorophenyl)-3-(4'-hydroxybenzoyl)benzofuran was obtained.
Reaction of 2-(4'-chlorophenyl)-3-(4'-hydroxy-benzoyl)benzofuran with epichlorohydrin and subsequent ring opening with isopropylamine according to the procedure of Example 7 gave 2-(4'-chlorophenyl)-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
Similarly, acylation of 2-(4'-tolyl)benzofuran with anisoyl chloride and subsequent demethylation with pyridine hydrochloride gave 2-(4'-tolyl)-3-(4'-hydroxybenzoyl)benzofuran.
Treatment of 2-(4'-tolyl)-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin followed by ring opening of the epoxy compound with isopropylamine as described in the procedure of Example 7 gave 2-(4'-tolyl)-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran which was converted to the corresponding hydrochloric acid salt as described in Example 1, m.p. 80°-87°.
In like manner, 5-bromo-2(p-bromophenyl)benzofuran is acylated with anisoyl chloride and the resulting 5-bromo-2-(4'-bromophenyl)-3-(4'-methoxybenzoyl)benzofuran is demethylated and the product treated with epichlorohydrin to give an epoxy compound which is subsequently opened with isopropylamine to give 5-bromo-2-(4'-bromophenyl)-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
A mixture of 27 g. (0.18 mol.) of 5-chlorobenzofuran, 28.5 g. (0.18 mol.) of butyric anhydride, 18 g. (0.20 mol.) of butyric acid and 5 g. (0.05 mol.) of phosphoric acid wasa refluxed for four hours then stirred at 25° for 12 hours. The reaction mixture was made basic with 10% aqueous sodium hydroxide, chloroform was added to the mixture and the layers were separated. The organic phase was washed with water, dried MgSO4) and concentrated in vacuo to give 2-butyryl-5-chlorobenzofuran.
A mixture of 31.5 g. (0.14 mol.) of 2-butyryl-5-chlorobenzofuran and 35 ml. of 98% hydrazine in 70 ml. of diethylene glycol was warmed for a few minutes on a steam bath. Then 23.3 g. of potassium hydroxide was added and the reaction mixture was refluxed for two hours. After cooling, water was added to the mixture and the resulting aqueous solution was extracted with benzene. The extract was washed with water, 10% aqueous hydrochloric acid and water, dried (MgSO4) and concentrated in vacuo to yield 2-n-butyl-5-chlorobenzofuran, b.p. 70°-75° (10-15 mm.).
2-n-Butyl-5-chlorobenzofuran (9.5 g., 0.046 mol.) was acylated with 8 g. (0.047 mol.) of anisoyl chloride as described in the procedure of Example 10 to give 2-n-butyl-5-chloro-3-(4'-methoxybenzoyl)benzofuran. Demethylation followed by reaction of the 2-n-butyl-5-chloro-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin and subsequent opening of the epoxy compound formed with isopropylamine was carried out as described in the procedures of Examples 9 and 7 to give the title compound.
A mixture of 14.2 g. (0.09 mol.) of cuprous phenylacetylide and 16.0 g. (0.08 mol.) of 2-bromo-4-chlorophenol in 130 ml. of pyridine was refluxed under a nitrogen atmosphere for 18 hours. The reaction mixture was cooled and poured into 600 ml. of water. The resulting precipitate was collected by filtration, washed with copious amounts of water and continuously extracted with ethanol for 12 hours. Removal of the ethanol in vacuo gave a residue which was chromatographed on an alumina dry column with hexane to give 5-chloro-2-phenylbenzofuran, m.p. 140°-143° (methanol).
Acylation of 5-chloro-2-phenylbenzofuran with anisoyl chloride was accomplished as described in the procedure of Example 10 to give 5-chloro-2-phenyl-3-(4'-methoxybenzoyl)benzofuran which was then demethylated and the product treated with epichlorohydrin as described above. Opening of the epoxide ring with isopropylamine as previously described gave the title compound.
A solution of 7.0 g. (0.017 mol.) of 2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran in 60 ml. of acetic anhydride was refluxed for six hours. The cooled reaction mixture was poured into ice water and the aqueous solution was extracted with chloroform. The extracts were washed with 5% aqueous sodium bicarbonate and water, dried (MgSO4) and concentrated in vacuo to give a mixture of 2-n-butyl-3-[4'-(2-acetoxy-3-N-acetylisopropylamino)-propoxybenzoyl]benzofuran, 2-n-butyl-3-[4'-(2-acetoxy-3-isopropylamino)propoxybenzoyl]benzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-N-acetylisopropylamino)propoxybenzoyl]-benzofuran which was separated by dry column chromatography on alumina with chloroform as eluant.
Alternatively, 2-n-butyl-3-[4'-(2-hydroxy-3-N-acetylisopropylamino)propoxybenzoyl]benzofuran was prepared by refluxing 4.9 g. (0.01 mol.) of 2-n-butyl-3-[4'-(2-acetoxy-3-N-acetylisopropylamino)propoxybenzoyl]benzofuran with 5 ml. of 10% aqueous sodium hydroxide in 20 ml. of water for 1 hour. After cooling, chloroform was added to the reaction mixture, the layers were separated and the organic phase was washed with water, dried (Na2 SO4) and concentrated in vacuo to give the desired product.
In like manner, the (2-acetoxy-3-N-acetylamino)-, (2-acetoxy-3-alkylamino)- and (2-hydroxy-3-N-acetylamino)-derivatives of the other (2-hydroxy-3-alkylamino)- benzofurans disclosed herein may be obtained.
By the procedure of Example 31, using propionic anhydride in place of acetic anhydride, the products are 2-n-butyl-3-[4'-(2-propionyloxy-3-N-propionylisopropylamino)-propoxybenzoyl]benzofuran, 2-n-butyl-3-[4'-(2-propionyloxy-3-isopropylamino)-propoxybenzoyl]benzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-N-propionylisopropylamino)propoxybenzoyl]benzofuran.
Similarly, using n-butyric anhydride, the products are 2-n-butyl-3-[4'-(2-n-butyryloxy-3-N-n-butyrylisopropyl-amino)propoxybenzoyl]benzofuran, 2-n-butyl-3-[4'-(2-n-butyryloxy-3-isopropylamino)propoxybenzoyl]benzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-N-n-butyrylisopropylamino)-propoxybenzoyl]benzofuran.
In like manner, the (2-propionyloxy-3-N-propionyl-amino)-, (2-propionyloxy-3-alkylamino)-, (2-hydroxy-3-N-propionylamino)-, (2-n- butyryloxy-3-N-n-butyrylamino)-, (2-n-butyryloxy-3-alkylamino)- and (2-hydroxy-3-N-n-butyrylamino) derivatives of the other (2-hydroxy-3-alkylamino)- benzofurans disclosed herein may be obtained.
Substitution of an equivalent amount of 2-n-butyl-3-[4'-(2-hydroxy-3-piperidino)propoxybenzoyl]benzofuran in the procedure of Example 31 for 2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran gives the title compound.
Likewise, substitution of the other (2-hydroxy-3-dialkylamino)-, (2-hydroxy-3-pyrrolidino)- or (2-hydroxy-3-morpholino)- benzofurans disclosed above gives the corresponding (2-acetoxy-3-substitutedamino)-benzofurans.
Substitution of the following benzofurans:
3-(3', 5'-dibromo-4'-hydroxybenzoyl)-2-ethylbenzofuran
3-ethyl-2-(4'-hydroxybenzoyl)benzofuran
2-(3'-chloro-4'-hydroxybenzoyl)benzofuran
2-(3'-fluoro-4'-hydroxybenzoyl)benzofuran
2-(2'-hydroxy-5'-methylbenzoyl)benzofuran
3-(3',5'-diiodo-4'-hydroxybenzoyl)-2-ethylbenzofuran
2-(2'-hydroxybenzoyl)benzofuran in the procedure of Example 7 for 2-n-butyl-3-(4'-hydroxy-benzoyl)benzofuran with subsequent opening of the intermediate epoxy compound with isopropylamine as described in Example 7 gives, respectively:
3-[3',5'-dibromo-4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-2-ethylbenzofuran
3-ethyl-2-[4'-(2-hydroxy-3-isopropylamino)propoxy-benzoyl]benzofuran
2-[3'-chloro-4'-(2-hydroxy-3-isopropylamino)propoxy-benzoyl]benzofuran
2-[3'-fluoro-4'-(2-hydroxy-3-isopropylamino)propoxy-benzoyl]benzofuran
2-[5'-methyl-2'-(2-hydroxy-3-isopropylamino)propoxy-benzoyl]benzofuran
3-[3',5'-diiodo-4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-2-ethylbenzofuran
2-[2'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]-benzofuran.
Substitution of an equivalent amount of 2-(chloro-methyl)butene in the procedure of Example 17 for 3-chloro-2-methylpropene followed by treatment of the product with m-chloroperbenzoic acid and subsequent opening of the epoxy compound formed with isopropylamine as described in Examples 17 and 7 gives 2-n-butyl-3-[4'-(2-ethyl-2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
In like manner, when an equivalent amount of 3-chloro-1-pentene is substituted in the procedure of Example 17 for 3-chloro-2-methylpropene and the product is treated with m-chloroperbenzoic acid and subsequently heated with isopropylamine as described above, there is prepared a mixture of 2-n-butyl-3-[4'-(1-ethyl-2-hydroxy-3-isopropylamino)propoxy-benzoyl]benzofuran and 2-n-butyl-3-[4'-(3-ethyl-2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran which is separated by chromatography on alumina.
When an equivalent amount of diethyl amine is substituted in the procedure of Examples 1 or 3 for isopropylamine or piperidine, 2-n-butyl-3-[4'-(2-hydroxy-3-diethylamino)propoxybenzoyl]benzofuran is obtained.
In a similar manner, reaction of 2-n-butyl-3-[4'-(2,3-epoxy)propoxybenzoyl]benzofuran with di-n-butylamine gives 2-n-butyl-3-[4'-(2-hydroxy-3-di-n-butylamino)propoxy-benzoyl]benzofuran.
Likewise, substitution of N-ethyl-N-methylamine in the procedure of Example 1 or Example 3 for isopropylamine or piperidine gives 2-n-butyl-3-[4'-(2-hydroxy-3-N-ethyl-N-methylamino)propoxybenzoyl]benzofuran.
Substitution of an equivalent amount of a benzofuran listed below:
5-bromobenzofuran
6-chlorobenzofuran
7-chlorobenzofuran
4-methylbenzofuran
5-methylbenzofuran
5-ethylbenzofuran in the procedure of Example 29 for 5-chlorobenzofuran followed by the synthetic steps of hydrazine reduction, acylation, demethylation, epoxide formation and opening of the epoxide with isopropylamine as described therein gives, ultimately, the following substituted benzofurans:
5-bromo-2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]benzofuran
2-n-butyl-6-chloro-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran
2-n-butyl-7-chloro-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran
2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-4-methylbenzofuran
2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-5-methylbenzofuran
2-n-butyl-5-ethyl-3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]benzofuran.
When an equivalent amount of 5-chloro-2-ethylbenzofuran is substituted in the procedure of Example 10 for 2-n-butylbenzofuran and the product is demethylated with pyridine hydrochloride, followed by treatment of the hydroxyphenyl benzofuranyl ketone with epichlorohydrin and subsequent ring opening of the resulting epoxy compound with isopropylamine as previously described, there is obtained 5-chloro-2-ethyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]-benzofuran.
In like manner, 3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-2-phenyl-7-trifluoromethylbenzofuran is obtained from substitution of an equivalent amount of 2-phenyl-7-trifluoromethylbenzofuran in the procedure of Example 10 for 2 -n-butylbenzofuran followed by the subsequent synthetic steps of demethylation, treatment with epichlorohydrin and heating the epoxy compound thus formed with isopropylamine.
A mixture of 17.4 g. (0.1 mol.) of 2-n-butyl-benzofuran and 19.1 g. (0.1 mol.) of 4-acetoxy-3-methoxy-benzonitrile in 20 ml. of trifluoroacetic acid is refluxed for three hours. The reaction mixture is cooled, diluted with 200 ml. of water and the resulting aqueous solution is extracted with ether. The extracts are concentrated to dryness and the residue is dissolved in 100 ml. of ethanol and heated with 20 ml. of 10% aqueous sodium carbonate for two hours. The mixture is concentrated, the residue extracted with ether and the extracts are dried and concentrated in vacuo to give 2-n-butyl-3-(3'-methoxy-4'-hydroxybenzoyl)-benzofuran.
2-n-Butyl-3-(3'-methoxy-4'-hydroxybenzoyl)benzofuran is reacted with epichlorohydrin and the resultant epoxy compound is heated with isopropylamine as previously described to give the title compound.
Substitution of an equivalent amount of α-bromo-p-nitroacetophenone in the procedure of Example 26 for α-bromo-p-chloroacetophenone gives 2-(4'-nitrobenzoyl)benzofuran.
Sodium borohydride (7.4 g., 0.2 mol.) is added portionwise to a rapidly stirred solution of 26.7 g. (0.1 mol.) of 2-(4'-nitrobenzoyl)benzofuran in methanol. The reaction mixture stirred at 25° for one hour then quenched by addition of water. The aqueous slurry is extracted with chloroform, the extracts are dried (MgSO4) and the solvent is removed in vacuo to give 2-(α-hydroxy-4'-nitrobenzyl)benzofuran which is immediately converted to the corresponding α-chloride by reaction with 14.3 g. (0.12 mol.) of thionyl chloride.
A mixture of 13.6 g. (0.36 mol.) of sodium borohydride and 14.4 g. (0.05 mol.) of 2-(α-chloro-4'-nitrobenzyl)benzofuran in 200 ml. of 80% aqueous diglyme is stirred at 50° for four hours. The reaction mixture is then cooled and hexane followed by 4.0 g. (0.1 mol.) of sodium hydroxide are added. The layers are separated and the organic phase is dried (MgSO4) and concentrated to give 2-(4'-nitrobenzyl)benzofuran.
2-(4'-Nitrobenzyl)benzofuran is acylated with anisoyl chloride as described in Example 10. Demethylation with pyridine hydrochloride as previously described gives 3-(4'-hydroxybenzoyl)-2-(4'-nitrobenzyl)benzofuran.
3-(4'-Hydroxybenzoyl)-2-(4'-nitrobenzyl)benzofuran (37.3 g., 0.1 mol.) is added in small portions to 56.4 g. (0.25 mol.) of stannous chloride dihydrate in 70 ml. of concentrated hydrochloric acid. The reaction mixture is heated at 50° for 3 hours, then stirred at 25° for 12 hours. Cooling (ice bath) enhances precipitation of the product salt which is collected by filtration and dissolved in water. The aqueous solution is made basic by addition of 10% aqueous sodium hydroxide and extracted with chloroform. The extracts are dried (MgSO4) and concentrated to give 2-(4'-aminobenzyl)-3-(4'-hydroxybenzoyl)benzofuran.
Reaction of 2-(4'-aminobenzyl)-3-(4'-hydroxy-benzoyl)benzofuran with epichlorohydrin followed by subsequent opening of the epoxy compound thus formed with isopropylamine as previously described gives the title compound.
A mixture of 2-(4'-aminobenzyl)-3-(4'-hydroxy-benzoyl)benzofuran (34.3 g., 0.1 mol.), 35.5 g. (0.25 mol.) of methyl iodide and 31.8 g. (0.3 mol.) of sodium carbonate in 250 ml. of water is refluxed for three hours then cooled to 25° and extracted with chloroform. The extracts are dried (MgSO4) and concentrated in vacuo to give 2-(4'-N,N-dimethylaminobenzyl)-3-(4'-hydroxybenzoyl)benzofuran.
Treatment of 2-(4'-N,N-dimethylaminobenzyl)-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin with subsequent opening of the epoxy compound thus formed with isopropylamine by methods outlined above gives the title compound.
A solution of 20 g. (0.105 mol.) of cuprous iodide in 400 ml. of ammonium hydroxide is poured with stirring into a solution of 15.4 g. (0.105 mol.) of m-nitrophenylacetylene in 500 ml. of ethanol. The reaction mixture is left to stand at 25° for 30 minutes then it is filtered and the product washed five times each with water, ethanol and ether to give cuprous m-nitrophenylacetylide.
A mixture of 5.3 g. (0.024 mol.) of o-iodophenol and 5.0 g. (0.024 mol.) of cuprous m-nitrophenylacetylide in 100 ml. of pyridine is refluxed for 7 hours under a nitrogen atmosphere. The reaction mixture is poured into water, the aqueous slurry filtered and the filtrate is extracted with methylene chloride. The extracts are washed with water, dried (MgSO4) and concentrated to give 2-m-nitrophenylbenzofuran.
Acylation of 2-m-nitrophenylbenzofuran with anisoyl chloride is accomplished as described in the procedure of Example 10. Demethylation with pyridine hydrochloride as previously described gives 3-(4'-hydroxybenzoyl)- 2-(3'-nitrophenyl)benzofuran.
2-(3'-Aminophenyl)-3-(4'-hydroxybenzoyl)benzofuran is prepared by reduction of 3-(4'-hydroxybenzoyl)-2-(3'-nitrophenyl)benzofuran according to the procedure of Example 40. Reaction of this compound with epichlorohydrin followed by ring opening of the resultant epoxy compound with isopropylamine as previously described gives the title compound.
Substitution of 32.9 g. (0.1 mol.) of 2-(3'-anilino)-3-(4'-hydroxybenzoyl)benzofuran and 15.6 g. (0.1 mol.) of ethyl iodide in the procedure of Example 41 for 2-(4'-aminobenzyl)-3-(4'-hydroxybenzoyl)benzofuran and methyl iodide, respectively, gives 2-(3'-N-ethylanilino)-3-(4'-hydroxybenzoyl)benzofuran.
Treatment of 2-(3'-N-ethylanilino)-3-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin followed by opening of the resultant epoxy compound with isopropylamine according to methods described above gives the title compound.
When equivalent amounts of o-hydroxyacetophenone or o-hydroxybenzophenone are substituted in the procedure of Example 26 for salicylaldehyde and α-bromo-p-methoxyacetophenone is substituted for α-bromo-p-chloroacetophenone, there are ultimately obtained 3-methyl-2-(4'-methoxybenzoyl)-benzofuran and 3-phenyl-2-(4'-methoxybenzoyl)benzofuran.
Demethylation of 3-methyl-2-(4'-methoxybenzoyl)-benzofuran with pyridine hydrochloride as previously described followed by treatment of the 3-methyl-2-(4'-hydroxybenzoyl)benzofuran with epichlorohydrin and subsequent opening of the intermediate epoxy compound with isopropylamine as described herein gives 2-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]-3-methylbenzofuran.
Similarly, 3-phenyl-2-(4'-methoxybenzoyl)benzofuran is demethylated and the resultant 2-(4'-hydroxybenzoyl)-3-phenylbenzofuran is reacted with epichlorohydrin followed by ring opening of the epoxy compound thus formed with isopropylamine to give 2-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]-3-phenylbenzofuran.
Acylation of 5-t-butoxy-2-ethylbenzofuran with anisoyl chloride according to the procedure of Example 10 with subsequent demethylation, reaction with epichlorohydrin and opening of the resulting epoxy compound with isopropylamine gives 5-t-butoxy-2-ethyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
Similarly, 2-(p-ethoxybenzyl)benzofuran is acylated and the 2-(4'-ethoxybenzyl)-3-(4'-methoxybenzoyl)benzofuran is demethylated, the product treated with epichlorohydrin and the resultant epoxy compound opened with isopropylamine to give 2-(4'-ethoxybenzyl)-3-[4'-(2-hydroxy3-isopropylamino)propoxybenzoyl]benzofuran.
When an equivalent amount of 4-methoxybenzofuran or 5-methoxybenzofuran is substituted in the procedure of Example 29 for 5-chlorobenzofuran there are prepared 2-n-butyl-4-methoxybenzofuran and 2-n-butyl-5-methoxybenzofuran.
Reaction of 2-n-butyl-4- and 5-methoxybenzofuran with 4-acetoxybenzonitrile and hydrolysis of the products with aqueous sodium carbonate as described in the procedure of Example 39, followed by reaction of the 2-n-butyl-3-(4'-hydroxybenzoyl)-4- and 5-methoxybenzofurans thus formed with epichlorohydrin and subsequent epoxide ring opening with isopropylamine as previously described gives, respectively, 2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]4-methoxybenzofuran and 2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]-5-methoxybenzofuran.
Ingredients Amounts ______________________________________ 2-n-Butyl-3-[4'-(2-hydroxy-3- isopropylamino)propoxybenzoyl]- benzofuran 100 mg. Calcium sulfate dihydrate 150 mg. Sucrose 25 mg. Starch 15 mg. Talc 5 mg. Stearic acid 3 mg. ______________________________________
The sucrose, calcium sulfate dihydrate and 2-n-butyl3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran are thoroughly mixed and granulated with 10% gelatin solution. The wet granules are screened, dried and then mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Ingredients Amounts ______________________________________ 2-(4'-Chlorobenzyl)-3-[4'-(2-hydroxy- 3-isopropylamino)propoxybenzoyl]- benzofuran 150 mg. Magnesium stearate 5 mg. Lactose 100 mg. ______________________________________
The ingredients are mixed and filled into a hard gelatin capsule.
Similarly, the other substituted benzofurans of Formula I or pharmaceutically acceptable acid addition salts thereof may be formulated into tablets and capsules by the procedures of Examples 47 and 48.
The compositions prepared as in Examples 47 and 48 are administered orally to a subject in need of coronary vasodilator activity within the dose ranges given hereabove.
Claims (17)
1. A pharmaceutical composition having coronary vasodilator activity, in dosage unit form, comprising a pharmaceutical carrier and, in an amount sufficient to produce coronary vasodilation, a substituted benzofuran of the formula: ##SPC9##
or a pharmaceutically acceptable acid addition salt thereof, in which:
R1 is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl;
R2 is hydrogen, lower alkyl or phenyl (CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, halogen, NH2, NH(lower alkyl) or N(lower alkyl)2 ; ##SPC10##
R4 is hydrogen, halogen, lower alkyl or lower alkoxy;
m is 1 or 2;
R5, r6 and R7 are hydrogen or one of R5, R6 and R7 is methyl or ethyl;
R8 is hydrogen or lower alkanoyl; and
R9 is NH(lower alkyl), N(lower alkyl)2, NH(benzyl), N(lower alkanoyl)(lower alkyl), piperidino, pyrrolidino, morpholino or succinimido.
2. The pharmaceutical composition of claim 1 in which R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoromethyl or chloro, R5, R7 and R8 are hydrogen, R6 is hydrogen or methyl and R9 is NH(isopropyl) or NH(t-butyl).
3. The pharmaceutical composition of claim 2 in which R1 is hydrogen, ##SPC11##
R4 is hydrogen or chloro and m is 1.
4. The pharmaceutical composition of claim 3 in which the substituted benzofuran is 2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
5. The pharmaceutical composition of claim 3 in which the substituted benzofuran is 2-n-butyl-3-[3'-chloro4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
6. The pharmaceutical composition of claim 3 in which the substituted benzofuran is 2-n-butyl-3-[4'-chloro2'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
7. The pharmaceutical composition of claim 3 in which the substituted benzofuran is 2-(4'-chlorobenzyl)-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
8. The pharmaceutical composition of claim 1 in which the substituted benzofuran is present in an amount of from about 100 mg. to about 600 formula: mg.
9. A method of producing coronary vasodilation which comprises administering internally to an animal, in an amount sufficient to produce coronary vasodilation, a substituted benzofuran of the formula: ##SPC12##
or a pharmaceutically acceptable acid addition salt thereof, in which:
R1 is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl;
R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, halogen, NH2, NH(lower alkyl) or N(lower alkyl)2 ; ##SPC13##
R4 is hydrogen, halogen, lower alkyl or lower alkoxy;
m is 1 or 2;
R5, r6 and R7 are hydrogen or one of R5, R6 and R7 is methyl or ethyl;
R8 is hydrogen or lower alkanoyl; and
R9 is NH(lower alkyl), N(lower alkyl)2, NH(benzyl), N(lower alkanoyl)(lower alkyl), piperidino, pyrrolidino, morpholino or succinimido.
10. The method of claim 9 in which R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with methyl, methoxy, trifluoro methyl or chloro, R5, R7 and R8 are hydrogen, R6 is hydrogen or methyl and R9 is NH(isopropyl) or NH(t-butyl).
11. The method of claim 10 in which R1 is hydrogen, ##SPC14##
R4 is hydrogen or chloro and m is 1.
12. The method of claim 11 in which the substituted benzofuran is 2-n-butyl-3-[4'-(2-hydroxy-3-isopropylamino)-propoxybenzoyl]benzofuran.
13. The method of claim 11 in which the substituted benzofuran is 2-n-butyl-3-[3'-chloro-4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
14. The method of claim 11 in which the substituted benzofuran is 2-n-butyl-3-[4'-chloro-2'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
15. The method of claim 11 in which the substituted benzofuran is 2-(4'-chlorobenzyl)-3-[4'-(2-hydroxy-3-isopropylamino)propoxybenzoyl]benzofuran.
16. The method of claim 11 in which the substituted benzofuran is administered in a daily dosage of from about 200 mg. to about 1,200 mg.
17. A method of producing anti-anginal activity which comprises administering internally to an animal, in an amount sufficient to produce anti-anginal activity, a substituted benzofuran of the formula; ##SPC15##
or a pharmaceutically acceptable acid addition salt thereof, in which:
R1 is hydrogen;
R2 is hydrogen, lower alkyl or phenyl(CH2)n where n is 0 or 1 and the phenyl moiety is optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, halogen, NH2, NH(lower alkyl) or N(lower alkyl)2 ; ##SPC16## ##SPC17##
R6 is hydrogen or methyl; and
R9 is NH(lower alkyl), N(lower alkyl)2 or NH(benzyl).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/551,581 US3975537A (en) | 1973-09-21 | 1975-02-20 | Pharmaceutical compositions and methods of producing coronary vasodilation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US399573A US3880891A (en) | 1973-09-21 | 1973-09-21 | Substituted benzofurans |
US05/551,581 US3975537A (en) | 1973-09-21 | 1975-02-20 | Pharmaceutical compositions and methods of producing coronary vasodilation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US399573A Continuation-In-Part US3880891A (en) | 1973-09-21 | 1973-09-21 | Substituted benzofurans |
Publications (1)
Publication Number | Publication Date |
---|---|
US3975537A true US3975537A (en) | 1976-08-17 |
Family
ID=27016673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US05/551,581 Expired - Lifetime US3975537A (en) | 1973-09-21 | 1975-02-20 | Pharmaceutical compositions and methods of producing coronary vasodilation |
Country Status (1)
Country | Link |
---|---|
US (1) | US3975537A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017382A1 (en) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
US6444688B1 (en) * | 1995-06-07 | 2002-09-03 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side chains |
CN102190609A (en) * | 2010-03-16 | 2011-09-21 | 凯惠科技发展(上海)有限公司 | 3-chloro-4-methoxy peroxybenzoic acid and intermediate and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3248401A (en) * | 1966-04-26 | Diethylaminoe hoxybenzoyl benzofurans |
-
1975
- 1975-02-20 US US05/551,581 patent/US3975537A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3248401A (en) * | 1966-04-26 | Diethylaminoe hoxybenzoyl benzofurans |
Non-Patent Citations (3)
Title |
---|
Derwent 21007v/12, Abstracting Belgium 804550 (6-3-74). * |
Derwent 719545-B, Abstracting Belgium 766392 Q 10-28-71. * |
Derwent 81178T-B, Abstracting Belgium 784260 Q 12-1-72. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017382A1 (en) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
US6444688B1 (en) * | 1995-06-07 | 2002-09-03 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side chains |
CN102190609A (en) * | 2010-03-16 | 2011-09-21 | 凯惠科技发展(上海)有限公司 | 3-chloro-4-methoxy peroxybenzoic acid and intermediate and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4001426A (en) | Substituted benzofurans and benzothiophenes | |
US3947470A (en) | Substituted benzofurans and benzothiophenes | |
US4424231A (en) | Compounds | |
US3983245A (en) | Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes | |
US5502216A (en) | Lignan analogues, methods of preparation thereof and anti-hyperlipemic agents | |
US4024273A (en) | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | |
US4117128A (en) | Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity | |
US3673218A (en) | Bichromonyl compounds | |
CA1302417C (en) | 2-substituted-1-naphthols as 5-lipoxygenase inhibitors | |
Hadimani et al. | Asymmetric total synthesis of (−) podophyllotoxin | |
FR2642065A1 (en) | BENZOCYCLOALCENYL DIHYDROXY ALKANOIC ACID DERIVATIVES, PREPARATION METHOD AND MEDICAMENTS CONTAINING SAME | |
US3984552A (en) | 6-Oxo-7-substituted and 7,7-disubstituted-6H-indeno-[5,4-b]furan (and thiophene) carboxylic acids | |
US3975537A (en) | Pharmaceutical compositions and methods of producing coronary vasodilation | |
US3880891A (en) | Substituted benzofurans | |
US3972900A (en) | 7-Substituted benzofuran derivatives | |
EP0089781B1 (en) | Bicyclic benzo fused compounds | |
US3985896A (en) | Benzophenalenofurans | |
Sargent et al. | Naturally occurring dibenzofurans. Part 1. A synthesis of cannabifuran | |
IE42353B1 (en) | Benzofurans and benzothiophenes and compisitions comprising them | |
JPH05140143A (en) | Pyranylphenylnaphthalenelactone as inhibitor of leukotriene biosynthesis | |
US4680404A (en) | Benzopyrans | |
US3484448A (en) | 2-(4-substituted phenyl)-3-lower alkyl-1,4-benzodioxane derivatives | |
IE64357B1 (en) | New heteroarotinoid derivatives processes for preparing them and pharmaceutical compositions containing them | |
Wu et al. | Preparation of 4, 4-dimethoxybutyl iodide from 1, 4-butanediol via the corresponding tosylate | |
US4456612A (en) | Benzisoxazole carboxylic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SMITHKLINE BECKMAN CORPORATION Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769 Effective date: 19820304 Owner name: SMITHKLINE BECKMAN CORPORATION, PENNSYLVANIA Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769 Effective date: 19820304 |